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Abstract 
The primary goal of this project is to increase specific uptake of anti-cancer therapeutics by 
nuclei of cancer cells. A lot of research has been done to target therapeutics specifically across 
plasma membrane of malignant cells. However not much research has been done to deliver 
them to their target cellular compartment where the drug elicits its pharmacological response. 
In case of majority of anti-cancer drugs the target is usually nuclei of cancer cells. Hence 
nuclear delivery of therapeutics is the next frontier of pharmaceutics. In this dissertation work 
this issue has been investigated. Initially in the first strategy adopted, novel peptide prodrug of 
doxorubicin was developed which may evade over-expressed efflux pumps on breast cancer 
cells. This approach may lead to increased uptake and higher drug accumulation in nuclei of 
cancer cells. L-val-L-val doxorubicin prodrug was synthesized following standard f-moc 
chemistry. The prodrug was analyzed for stability, cellular and nuclear uptake and interaction 
with efflux and peptide transporters. Breast cancer cells (T-47D) were grown on polystyrene 
12-well plates.  The prodrug Val-Val-doxorubicin was found to be very stable in breast cancer 
cell homogenate. It was able to evade efflux pumps. The prodrug penetrated cytoplasm and 
nuclei of cancer cells by interacting with peptide transporters over-expressed on plasma and 
nuclear membrane of T-47D.Uptake of prodrug was found to be 10 fold higher than parent 
drug. Peptide prodrug derivatization of doxorubicin has potential to evade efflux pumps and 
increase availability and nuclear accumulation of doxorubcin in breast cancer cells. However 
due to its stability the prodrug did not biorevert to its parent drug in therapeutic concentration. 
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Hence alternative approaches were investigated. As part of this alternate approach  novel 
nuclear localization signal (NLS) peptide analogues have been designed that can carry 
therapeutic molecules specifically into  nuclei of cancer cells. This strategy might be able to 
reduce toxicity to non-malignant cells by delivering anticancer drugs to subcellular organelle 
i.e. nucleus of cancer cells preferentially. Native NLS peptide-conjugated drugs can reach 
nucleus of any cell non-specifically. However the overarching challenge is to enhance drug 
uptake across plasma and nuclear membranes to enhance anticancer drug delivery in drug 
resistant cancer cells. Adenoviral fiber protein (AFP) that encodes for NLS has been known to 
penetrate both plasma and nuclear membrane nonspecifically. Therefore novel NLS peptide 
analogues have been synthesized by substitutions of NLS sequence specific amino acids for 
targeting cancer cells primarily. Specific amino acids of native NLS have been substituted 
based on hydrophobic interactions between the peptides with plasma membrane and nucleo-
pore complex (NPC) that can influence cytoplasmic and nuclear transport. These peptides can 
carry therapeutics selectively to nuclei of cancer cells simultaneously evading normal cells. 
Five NLS peptides have been synthesized. These peptides were synthesized by AAPtech 
automated peptide synthesizer. Following synthesis, the peptides were purified by a shimadzu 
Preparative HPLC which was confirmed by HPLC-MSMS. Confocal and quantitative uptake 
studies with various cancer and corresponding non-cancerous human cell lines were 
performed. It was observed that two (NLS3 and NLS5) peptides are specific for targeting 
cancer cell nucleus.  It has led to an unequivocal conclusion that these novel peptide analogues 
can selectively bind to plasma membranes of cancer cells and target NPC simultaneously. 
Following screening of peptides which can function as targeting moieties, nanoparticle 
formulation was developed to deliver anti-cancer drugs. One of the important parameters for 
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nuclear drug delivery is size. The nucleopore complex has a diameter of 30 nm. Cargo with 
30-40 nm can enter the NPC passively. However particles higher than 40 nm need to be 
actively transported across NPC. It has been reported that particles with 60-70 nm with anti-
cancer drugs can be delivered into nucleus with localization signals. This is the target size 
which has been achieved for doxorubicin loaded nanoparticle.  PLGA-PEG-NH2 was used as 
polymer for preparation of doxorubicin loaded nanoparticles. This is because of availability of 
NH2 group at the end of PEG group for conjugation of peptide moiety for targeted delivery 
following optimization of size. Nanoparticles were prepared by nanoprecipitation method. 
Parameters like effect of solvent, polymer concentration, effect of aqueous phase volume, drug 
concentration were optimized to yield a nanoparticle of size range 60-70 nm as this size can 
be taken up by nucleus if actively aided by nuclear localization signal. Following preparation 
of nanoparticle of optimized size, screened peptides (NLS3 and NLS5) with maximum affinity 
for cancer cell nuclei with minimal entry into corresponding non-malignant cells were 
conjugated to nanoparticles. Targeted nanoparticles were investigated for its active targeting 
property in a 3D model of breast cancer. It was observed that nanoparticle with NLS conjugated 
to its surface delivered higher concentration of doxorubicin compared to unconjugated 
nanoparticle or free doxorubicin. 
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CHAPTER 1 
LITERATURE REVIEW 
            1.1 Cancer 
Cancer is a major malignancy which has claimed numerous lives worldwide. 
Despite huge resources being utilized to develop cancer therapeutics, no effective cure has 
been found so far. Hence there is a need to look at emerging technologies for a solution. 
Nanoparticle is one such technology that have become more feasible and popular in the 
past few years. Though, it has not emerged as a drug delivery platform for cancer 
therapeutics, but it has shown enormous promise. Alternatively, different types of materials 
such as polymer, lipid, magnet, metal based nanoparticles have been developed to enhance 
the effectiveness of current treatment.  
            1.2. Efflux and Influx Transporters  
However multidrug resistance caused by efflux pumps localized on plasma as well 
as nuclear membrane of cancer cells is a major barrier to delivery of these agents. Multidrug 
resistance (MDR) significantly compromises clinical outcome [1].  MDR in cancer cells is 
associated with over-expression of efflux pumps. When MDR genes are over-expressed, 
tumor cells develop resistance to a wide range of structurally and functionally unrelated 
therapeutic agents. MDR genes produce three main types of efflux proteins: P-glycoprotein 
(P-gp), multidrug resistance associated proteins (MRP) and breast cancer resistance protein 
(BCRP). Such efflux proteins play a crucial role in protecting cells against xenobiotics [2-
11]. However in disease condition, they may identify drugs as foreign agents and efflux 
them out of cells.  Multi-drug efflux pumps are localized on both plasma and nuclear 
membranes which may pump cytotoxic agents out of cytoplasm and nucleus respectively 
[12-14]. Development of resistance to chemotherapeutics is one of the major factors 
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responsible for low efficacy of anti-cancer chemotherapeutic drugs. Several mechanisms 
can lead to development of drug resistance. However multidrug resistance due to 
overexpression of efflux pumps like P-glycoprotein (P-gp) is a major reason of drug 
resistance[15]. MDR1 gene encodes P-gp which is a transmembrane protein. It is a member 
of the ATP-binding cassette family of drug transporters. P-gp is responsible for efflux of 
many of hydrophobic, neutral, and positively charged drugs out of the cell.  Expression of 
P-gp is a function of normal cellular defense system against xenobiotics [16].Unfortunately 
in majority of human cancers, enhanced expression of P-gp causes reduced survival and 
poor prognosis [17, 18].  
 Drug accumulation inside cell is a complicated process [19]. It involves cellular 
drug uptake, retention and distribution. Generally most hydrophobic chemotherapeutic 
agents enter cell by passive diffusion. However efflux transporters bind drug molecule and 
pump it outside. At any given point of time, accumulation of a drug inside cells is the 
difference between amount of drug uptake and effluxed amount.  Drug efflux caused by P-
gp lowers intracellular net drug uptake or accumulation. 
 Therapeutic efficacy of doxorubicin in cancer treatment is restricted primarily due 
to emergence of drug resistance. Reversal of this process may lower dose necessary to 
eradicate tumor which will reduce drug toxicity. Doxorubicin efficacy is limited because 
of cardiotoxicity, a dose-dependent phenomenon and an important adverse effect that 
impairs treatment, outcome and survival[20]. Chintamani et al. [21] reported that P-gp 
positive patients are clinically less responsive to doxorubicin compared to P-gp negative 
group. 
 Due to drug exposure, tumor cells produce elevated levels of MDR proteins, 
resulting in enhanced efflux and diminished accumulation of anticancer agents [22, 23]. 
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Thus, progressively higher doses are needed to achieve cytotoxic concentrations in cancer 
cells. But, such doses may cause toxicity to non-malignant cells such as bone marrow, 
cardiac and renal cells. Therefore,  primary objective of this work is to design a prodrug 
(PD) of anticancer agent (doxorubicin) which can evade efflux pump, recognized and taken 
up by influx transporters and lower drug resistance. Influx transporter targeted PD design 
may be a promising strategy which can bypass efflux pumps and enhance intracellular drug 
accumulation in BC cells [24, 25]. It involves conjugating small peptide to anticancer 
agents which may serve as substrates to the membrane influx transporters, such as human 
peptide transporter (hPEPT), highly expressed on BC cells.  
  PEPT 1 and 2 belong to the peptide transporter (PTR) family [26]. These proteins 
are expressed as integral membrane proteins and are responsible for uptake of di- and 
tripeptides across membranes. These transmembrane transporters may be able to transport 
peptidomimetics and peptide conjugated therapeutic agents. 
            1.3. NLS and CPP 
Nuclear Localization Signal (NLS) peptide is a prime facilitator for the transport of 
large peptides and proteins into nucleus and it can be classified as classical and 
nonclassical. Classical NLS peptides are short sequences of basic amino acids of AFP and 
can be monopartite or bipartite. Monopartite NLS peptides contain single short stretch of 
basic amino acids whereas bipartite NLS contain two different stretches of basic amino 
acids separated by a space sequence of 10-12 amino acids. A third, less studied class of 
NLS, contains charged/polar sequence with interspersed nonpolar amino acids. Classical 
NLS may be recognized by Imp α/β or by Imp β alone. Non-classical NLS does not contain 
stretches of basic amino acids[27].  
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Cell Penetrating Peptide (CPP) and NLS are peptides, which as their names suggest 
aids cargo to cross cell membrane and nuclear membrane respectively. They have been 
widely used as tools to deliver therapeutics. This includes both small molecules and 
macromolecular therapeutics. Hence CPP can be used to deliver therapeutics which can act 
in the cytoplasm. NLS can carry therapeutics into the nucleus where it is supposed to elicit 
action. This includes most of the anti-cancer drugs. Sometimes a single peptide contains 
both CPP and NLS sequence which can carry cargo across both cell and nuclear membrane.  
Cell-penetrating peptides (CPPs) are promising tools to deliver different cargoes 
across cell membrane. Efficacy of CPP in delivery of macromolecules like 
oligonucleotides, small interfering RNAs (siRNAs), proteins and peptides drugs, as well 
as different pharmaceutical carriers like nanoparticles, liposomes have been investigated 
extensively. The results have been found to be promising.  
 Therapeutics are not always able to reach their target in therapeutic concentrations. 
Targeting of therapeutics to specific organelles located inside the cell might enhance the 
efficacy of drug delivery systems. This could also lead to successful organelle-targeted 
therapy. The subcellular organelle that could be potential targets include nucleus, 
mitochondria etc. 
However the trajectory of translating molecular hits into therapeutics of clinical 
significance is restricted due to numerous problems. Most compounds fail due to 
unfavorable pharmacokinetic profile and failure of molecules to reach intracellular targets 
in therapeutic concentration. Many pharmaceutical formulations like liposomes, micelles, 
nanoparticles have been utilized extensively to deliver therapeutics. However these drug 
delivery platforms have not been very effective as they depend heavily on the phenomena 
of passive absorption to reach their desired site of action. 
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Attempts have been made to use targeting moieties like antibodies, peptides to 
actively transport therapeutics or formulation of therapeutics to their respective site of 
action.  Clathrin-dependant endocytosis has often been a target of this approach. The 
disadvantage of endocytic pathway is that it often restricts escape from the endosome. This 
leads to a majority of drugs/drug carriers being trapped in endosomes, followed by 
lysosomal degradation.  
 After natural polycationic CPPs and NLS peptides were discovered it was observed 
that these peptides have potential to act as drug carriers and they increase cellular/nuclear 
entry[28]. This created an enormous scope for delivery of therapeutics to their targeted site 
of action. 
Proteins accumulate in the nucleus through nuclear pore complex (NPC)[29].  This 
mechanism was initially observed in nucleoplasmin, an acidic protein that binds histones 
H2A and H2B during nucleosome assembly [30-34]. In vertebrates nuclear pore complex 
weighs 125Mda in mass and contains 50-100 polypeptides. Thus, for macromolecules to 
cross the NPC, a signal mediated transport mechanism is involved. Although several 
pathways exist for nuclear transport, classical NLSs that contain one or more clusters of 
basic amino acids are well known and characterized[35]. NLSs are stretches of residues in 
proteins that facilitate importing protein residues into the nucleus. Small molecules less 
than 40-45kda diffuse freely in and out of the nucleus through nuclear pore complexes 
using soluble carrier proteins. However, the nuclear import of larger molecules, is an 
energy-dependent process mediated by specific targeting NLSs [36]. These oligopeptides 
that are less than 10 amino acids binds directly to a group of proteins called importins. The 
structural and functional domains of importin-α consists of a short basic N-terminal called 
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as Importin-β binding domain [27, 37, 38]and a large NLS-binding domain called 
armadillo (Arm) which has domain of nucleoporin repeats[39]. 
 Importin-α transports cargo into the nucleus, and the importin-α is further 
recognized by importin-β to form a heterotrimer complex that interacts with the 
hydrophobic repeat domains of nucleoporins (Nups) that constitute the NPCs[40]. The α- 
subunit of importin binds the NLS, and the β- subunit recognizes it and allow docking at 
the nuclear pore complex. Importin β may be considered as a mediator [40]. Ran, a GTPase 
facilitates translocation of the importin-cargo complex across the nuclear pore by binding 
to importin-and induces a conformational shift that results in release of cargo into the 
nucleoplasm. Importin-RanGTP complexes are dissociated through the hydrolysis of GTP 
by Ran in the cytoplasm. Then, importin protein, becomes available for further cycles of 
cargo import[40]. 
           1.4 Classes of CPPs 
It has been reported that Transactivator of Transcription (TAT) protein of HIV can 
cross cell membranes and be efficiently internalized. It has also been reported that similar 
approach to analyze efficacy of truncated versions of TAT [41]. This led to identification 
of a minimal sequence that allowed cell entry. Over the past several years more than 100 
peptidic sequences (of different amino acid chains) have been identified. These peptides 
possess the capacity to carry different kinds of therapeutics to their site of action. 
 CPPs can be classified according to their origin or sequence characteristics. Most 
CPPs are not specific towards any particular type of cell or tissue. The binding of CPP 
depends mainly on the positively charged amino acids present in the CPP sequence. These 
positively charged amino acids are in most cases arginine and lysine. The uptake of the 
CPP is mediated by electrostatic interactions. These interactions take place cell-surface 
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which has a net negative charge due to presence of glycoproteins. Examples include TAT 
proteins and polyarginines. 
The second CPP class consists of peptides which are highly amphipathic. In this 
class of peptides lysine residues are mainly responsible for their characteristics. Examples 
of this class of CPP are MAP [42], transportan [42] and Pep-1[42]. Third class of CPP has 
the charged and hydrophobic residues separated lengthwise on the sequence of CPP. This 
arrangement of amino acid residues is observed in vascular endothelial-cadherin (pVEC) 
and MPG peptides. 
            1.5. Classes of NLS 
NLS are classified as monopartite NLSs, containing a single cluster of basic amino 
acids, and bipartite NLSs, containing two basic clusters. These 2 basic clusters function 
were shown to function independently [43] the identity of amino acids in spacer region that 
separate these basic clusters do not control their function of nuclear targeting signal.  
Monopartite cNLSs are characteristic of SV40 large T antigen NLS 
(126PKKKRRV132) and bipartite cNLSs are characteristic of nucleoplasmin NLS 
(155KRPAATKKAGQAKKKK170) [12].  Consecutive residues of monopartite NLS, from 
the N-terminal lysine are referred to as P1, P2, etc[43]. There are various key requirements 
for a sequence to be classified as cNLS as per kinetic [44] and thermodynamic studies [45]. 
These studies indicate that a monopartite cNLS requires a lysine in the P1 position, 
followed by basic residues in positions P2 and P4 to yield a loose consensus sequence of  
+K (K/R) X(K/R). in-vitro binding affinity data of importin-α with cNLS in vitro 
correlates with the steady state nuclear accumulation and import rate of the corresponding 
cNLS cargo in vivo [46] . 
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            1.6. NLS Peptides in Molecular and Cellular Processes 
Histones that pack eukaryotic DNA into nucleosomes are major structural proteins 
in eukaryotic chromosomes. These small, basic proteins encompass the H1 linker histones 
and the core histones H2A, H2B, H3 and H4. The four core histones H2A, H2B, H3 and 
H4 form histone octamer. The linker histones H1 are rich in Lysine, H2A and H2B are 
moderately lysine-rich and H3 and H4 are rich in arginine [46]. H2AThe size of the H1 
linker histones is about 22Kda and that of the core histones varies between 15 to 22 KDa.  
The nuclear import of histones occurs by an active transport mechanism involving NLS 
where as other small proteins are transported by simple diffusion[46].  
Nuclear localization signals (NLS) of histones can be subdivided into two different types 
of signal structures. H1 histones are transported by a heterodimeric import receptor 
complex consisting of importin-β and importin-7, whereas, the core histones are 
transported by anyone of these four receptors: importin-β, importin 7, importin 5 and 
transportin [46]. The core and linker histones are substrates that are transported into the 
nucleus for the formation of new nucleosomes formation and take part in two different 
levels of chromatin organization [46].  
 NLS are implicated in transcriptional and post-translational mechanisms involving 
both nucleus and cytoplasm.  Ku70 is a protein that participates in DNA repair, 
chromosome maintenance, transcription regulation and V(D)J recombination .The nuclear 
and sub-cellular localization of Ku complexes,Ku70 and Ku80 are of immense interest to 
researchers, particularly those investigating their diverse functions[47].   
 Several NLS controls the import of mineralocorticoid (MR) receptor that is a 
nuclear hormone receptor selectively transmits corticosteroid signals [48, 49].  MR also 
has high affinity towards glucocorticoids than for the mineralocorticoids and the 
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glucocorticoid receptors (GR) [50, 51]. In kidney tubules and distal colon epithelial tissues, 
MR signaling plays an important role in expression of 11β- hydroxysteroid dehydrogenase-
2, which converts cortisol or corticosterone to inactive keto metabolites 51.  Each of these 
NLS signals is uniquely regulated, exerting specific effect that one signal is ligand-
independent (NLS0), the second is agonist-specific (NLS2), and the third is responsive to 
both steroid agonists and antagonists (NLS1). The signals were also found to be  
biochemically distinct, with NL1 composed of a bipartite basic motif, NL2 lacked an 
obvious basic motif and dependent on LBD (Ligand-binding domain) conformation, and 
NL0 required a serine/threonine motif representing a  new class of NLS.  Nuclear receptors 
are typically bidirectional with the exception of this MR that was found to be 
unidirectional, transported from cytoplasm to the nucleus. The regulation of steroidal 
signaling is a complex interplay of these three NLSs within the MR  
             1.7. NLS in Gene Delivery   
 Nuclear membrane is the primary barrier in expressing a transgene in vitro.  Gene 
delivery technologies rely on successful translocation of exogenous DNA through the 
nuclear membrane. Viral gene therapy has limitations due to triggering response of host 
immune system, thus rendering it ineffective for clinical purposes. The use of electrostatic 
binding of DNA to cationic proteins that contain NLS, peptides, and sequence specific 
binding of DNA to importin/exportin  have been attempted[52-57]. Novel means to 
enhance the transfection efficiency by using a single NLS sequence to transport the 
exogenous DNA to nucleus by irreversible binding at one end with the NLS sequence 
indicates the link between plasmid and a NLS peptide in gene delivery technology [58].    
Another alternative to viral gene delivery methods with clinical potential are 
nonclassical NLS sequences. Both classical and non-classical NLS sequences have been 
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studied for rate limiting DNA delivery to the non-dividing cells[59]. A nonclassical sequence 
called as M9, isolated from heterogeneous nuclear ribonucleoprotein A1 (hnRNP A1) was 
found to surge the gene expression by more than 10 to 150-fold in many types of cells. The 
effect of lipofectamine-M9 construct was shown to increase the transfection efficiency by 
20-fold from the baseline in mouse 3T3 fibroblast cell lines. Studies have also documented 
the effect of M9-lipofectamine construct in oesophageal and mucosal cell lines [60]. 
Twenty to hundred fold enhancement of efficiency was observed in M9-lipofectamine 
mediated transfection in embryonic-derived retinal ganglion cells, rat pheochromocytoma 
(PC12) cells, embryonic rat ventral mesencephalon neurons, and clinically relevant human 
NT2 cells or retinoic acid-differentiated NT2 neuron [61]. 
           1.8. NLS-derived Peptides as Therapeutic Tools 
 N50 peptide selectively targets Imp α5, offering a scope for applying NLS-derived 
peptides as new tools to modulate inflammatory disorders [62]. N50 peptide forms stable 
complexes with multiple importins /karyopherins α and also interaction with importin (Imp 
α5) displays specific, high-affinity binding. The nuclear import pathway of NF-Kβ 
members is mediated by importin-β that interacts with NPC, and the adaptor proteins 
importin-α, which binds directly to the NLS-motif [63]. 
In vascular smooth muscle cells and macrophages, NLS peptides were found to 
block the importin-α –mediated import of NF-kβ, preventing pro-inflammatory gene 
expression, cell migration, and oxidative stress. In vivo studies of atherosclerosis models, 
demonstrated the inhibitory activity of NLS peptides by attenuating NF-Kβ activation, 
preventing development of lesions at early, as well as, in advanced stages [64].  Cyclic 
peptide sequence containing NLS region of the Rel family of P50 has been shown to inhibit 
nuclear import of classic NF-kβ complex responsible for development of atherosclerosis 
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[64, 65].  Cell penetrating peptides of different kinds have been developed to directly 
inhibit NF-kβ signaling pathways of which NLS sequence of P50 inhibits gene expression 
by blocking NF-Kβ activity[66]. Moreover, the P50 NLS peptide administered mice-model 
prevented vascular inflammation by controlling the expression of TNF-α and IL-6 
cytokines which generally enhance local inflammatory response in the lesions[67].  
             1.9. NLS-tagged Nanocarriers 
 NLS-cationic solid lipid nanoparticles (SLN) has been utilized in gene delivery. 
Some cationic lipids used for the preparation of lipid nanoparticles are        CTAB,     N-
[1-(2,3-dioleyloxy)propyl]-N,N,Ntri-methylammoniumchloride (DOTMA), and 
dimethyldioctadecylammonium bromide (DDAB). Although cationic lipids are toxic to the 
cells addition of ester bonds make these more biodegradable and less cytotoxic [68]. In a 
study, transferin, a glycoprotein that binds to iron, was linked onto PEG-PE to form Tf-
PEG-PE as ligands for surface modification of a nanocarrier:  dexamethasone (synthetic 
nuclear receptor) conjugated with a cationic lipid LHON, carrying a gene pEGFP to the 
target nuclei of HepG2 cell line and mice model[68]. 
Vectors containing Tf-PEG-PE-modified SLNs/ pEGFP (Tf-SLNs/pEGFP) had 
high transfection efficiency of around 90% than the vectors without the dexa-LHON 
conjugate [68]. 
             1.9.1 Micelles 
Conjugation of NLS with block copolymer micelles (BCM) for efficient drug 
delivery to the targeted nucleus is another area of intense research for improving the 
efficacy of formulations. Active targeting of BCMs conjugated with NLS peptides 
exhibited a 5-fold increase in tumor uptake in HER2-overexpressing BT-474 tumors 
12 
 
(breast cancer cells). It also lead to corresponding greater level of cellular uptake and 
nuclear localization, compared to the non-targeted formulations [68].  
Polymeric micelles fabricated with NLS exhibited enhanced cellular uptake of 
higher amounts of drug in the nuclei of the target cells. Cholesterol modified glycol 
chitosan (CHGC) conjugated with NLS was formulated with Doxorubicin, and 
administered to Hep G2 cell line [69-73]. The IC50 values of micelle-doxorubicin 
formulation, micelle-doxorubicin-NLS conjugate and free doxorubicin against HepG2 cell 
line were 0.591, 0.171 and 4.063 μg/mL, respectively. The IC50 values of micelle-
doxorubicin-NLS conjugate against HeLa cell line was 6.96 times lower than that of free 
Doxorubicin. A nuclear localization signal conjugated doxorubicin loaded Poly(d,l-lactide-
co-glycolide) nanoparticles (NPs), exhibited lower IC50 value  of 2.3µM/ml compared to 
that of free doxorubicin’s 17.6µM/ml and unconjugated NP’s7.9µM/ml[74].  Doxorubicin 
released from the micelle-doxorubicin and micelle-doxorubicin-NLS conjugate over 
48 hours was almost 50% in vitro [75]. However, the sustained release of doxorubicin 
loaded with NP was observed to be 63% over 60 days. Moreover, the proportion of cells 
in G2/M arrest phase were higher in the NLS conjugated NPs treatment groups than in the 
group treated with the drug in solution and unconjugated NP, indicating the increased 
nuclear uptake of Doxorubicin-NP-NLS conjugate. 
             1.9.2. Drug-NLS Conjugate 
Trastuzumab, a monoclonal antibody that targets human epidermal growth factor 
(HER2/neu), used to treat breast cancers, has only an overall  response rate of 7%–35%, 
depending on the level of HER2/neu expression[76, 77]. Radio immunotherapy with 
Trastuzumb is believed to increase the cytostatic activity of the drug by localizing the 
radiation in the nucleus. It’s murine mAb analog 4D5, labeled with β-emitters such as 131I, 
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90Y, or 188Re or α-emitters like the 212Pb, 213Bi, 211At, or 225Ac[78-84], has been 
shown to inhibit the growth of HER2/neu-positive human breast, ovarian, nasopharyngeal, 
prostate, colon, and pancreatic cancer cells in vitro and   in vivo in xenograft mouse models. 
However, β-emitters and α-emitters have limitations such as hematologic toxicity and short 
half-lives, redistribution of long-lived α-emitters to normal organs, respectively[78-86].  
Trastuzumab conjugated with NLS and labeled with 111In using diethylene triamine 
penta acetic acid (DTPA) for receptor-mediated internalization of the drug by low-energy 
augur radio immunotherapy showed enhanced internalization of 111Intrastuzumab (made 
of 6 NLS-peptides) in SK-BR-3, MDA-MB-361, and MDA-MB-231 cells[87]. The levels 
of HER2/neu expression in SK-BR-3, MDA-MB-361, and MDA-MB-231 human breast 
cancer cells were very high, intermediate and low, respectively[87].  
Thus, by selectively exploiting the biological property of NLS peptides for 
enhancing the drug delivery to target nucleus offers wide range of therapeutic options in 
chemotherapy, eliciting immunomodulatory effects, and radio immunotherapy. 
CPPs and NLSs have been documented to aid intracellular/nuclear delivery of many 
biomolecules. The absence of cell specificity of these peptides along with their 
susceptibility to proteolytic cleavage under physiological conditions is a major drawback. 
However several efforts are being made to circumvent this bottleneck. Smart carriers as 
described in this review might be an option. An external local trigger can also be employed 
to enhance a carrier’s cargo release. CPP/NLS modified nanocarriers should be designed 
in such a way that during the first phase of their delivery, surface CPP/NLS moieties are 
sterically shielded. After reaching their target (passively or actively), CPP/NLS should be 
exposed under unique local conditions to enhance penetration of carrier through cell 
membrane followed by intracellular delivery of bioactive cargo at the target.  Metabolism 
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of cancer cells and additional pathological conditions provide a unique challenge that 
require specific triggers through CPP exposure to affect intracellular drug delivery. The 
fact that delivery platform technologies have matured into potentially useful CPP-based 
therapeutics and delivery agents provides optimism for a wide range of therapeutic 
applications which should eventually pave the way for their combined usefulness in the 
clinic. 
           1.10. Nanoparticles 
Nanoparticles are an emerging technology which is a subject to active research. A 
lot of interesting and clinically significant investigations involving nanoparticle technology 
are under process. Due to the above mentioned reasons there is a need to have an 
understanding of the direction drug delivery for cancer chemotherapy is evolving.  Size of 
Nanoparticle varies in the region of 5–100 nanometers[88]. There are numerous 
components from which nanoparticles can be prepared. Nanoparticles can be prepared 
from polymer like Poly-lactide-co-glycolide (PLGA), and Poly-caprolactone (PCL). Due 
to different components used to prepare nanoparticles, there are many possible functional 
groups present on the surface of the nanoparticles. Many targeting agents can be conjugated 
on the surface or in the core of nanoparticles 
1.11. Different Applications of Nanoparticles for Cancer Treatment and Related 
Literature 
   1.11.1. Diagnosis: nanoparticles have wide ranging application as diagnostic tools, of 
which   few are   discussed in this section. 
           Lipid-based Nanoparticles 
O’Halloran et al.[89] have explained the use of active forms of platinum and arsenic 
drugs into liposome for treatment and/or diagnostic of cancer.  
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         Magnetic Nanoparticles 
Chauhan et al. [90] described magnetic nanoparticles (MNP) comprising of a core 
MNP, first layer of cyclodextrin over the core MNP, and a second layer of pluronic polymer 
over cyclodextrin layer. MNPs of the invention, and clusters thereof, significantly improve 
existing nanoparticle formulations by offering improved sustained release, enhanced 
cellular uptake, stability,  reduced particle cluster size, and haemocompatibility, rendering 
them applicable for far-reaching varsity of biomedical applications, including but not 
limited to drug delivery, in vivo imaging, hyperthermia applications, MRI visible targeting, 
photodynamic therapy, and chemotherapy. MNP-curcumin formulations were 
administered intra-tumorally in nude mice to monitor inhibitory effect on pancreatic tumor 
growth. 
Zhang et al.[91] have advanced the use of glypican-3 for targeting liver cancer cells 
using multifunctional nanoparticles for diagnosis of liver and gallbladder tumor cells. This 
method is achieved through detecting and then labelling of liver cancer cells using an anti-
glycipan-3 antibody as a targeting agent.  Liver cancer cells are labelled by magnetic 
nanoparticles linked with anti-gycipan-3 antibody. Then MRI is used to detect the labelled 
liver cancer cells. This method is very sensitive as it can detect up to about 106 liver cancer 
cells. Anti-gycipan-3 antibody can be replaced by IgG, IgG Fab, or F (ab’). Nanoparticles 
can consist of chitosan or PEO either in the inner core or on the outer surface. 
            Other Nanoformulations 
Desai and Soon-Shiong[92] described various methods of enhancing therapeutic 
uptake in a targeted tissue and enhancing effectiveness of treatment with a therapeutic 
agent by administering  nanoparticle composition comprising albumin and a poor water 
soluble drug such as taxane with the therapeutic agent. Desai and Soon-Shiong have 
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observed that uptake of therapeutic agent co-administered with nanoparticles comprising 
albumin and taxane to a target tissue (such as tumor) is greater compared to the uptake of 
therapeutic agent not co-administered with taxane nanoparticle composition. Nanoparticles 
comprising albumin and a taxane, namely Abraxane, have shown substantial improvement 
in therapeutic efficacies in vivo for treating various tumors. 
Samid et al.[93]described an approach of efficiently expanding T cells that is 
responsible for specifically targeting cancerous cells in order to reduce the size and number 
of cancerous cells in vivo. The invention defines a composition containing nanoparticles 
coated with MHC class I/II molecules that provides the tumor specific antigens and other 
co-stimulatory molecules. The purpose behind using such molecules is to expand antigen-
specific anti-tumorigenic T cells to heights that have not been achieved in current 
immunotherapeutic techniques. Liangfang et al.[94]have defined a membrane encapsulated 
nanoparticle for diagnostic and treatment of gastrointestinal and stromal tumors. 
 1.11.2. Drug Delivery:  Perhaps the most important application of nanoparticles is in the 
field   of drug delivery. Maximum research effort which involves nanoparticles are related 
to drug delivery applications. 
          Polymer-based Nanoparticles 
Oliver S. Fetzer [95] described the use of controlled release cyclodextrin-based 
polymer (CDP) systems for delivery of therapeutic peptides which is provided as a particle 
(e.g. nanoparticles). This will lead to an increment in effectiveness of therapeutic peptide 
as well as curtailing of problems related with patient compliance. Conjugation of CDP to 
therapeutic peptides described has been obtained in several ways such as through a lipid 
linker. This attachment may lead to improvement in therapeutic efficacy, stability, 
solubility, and reduced toxicity of the therapeutic peptide specially when used in vivo. 
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Alternatively the formulation might be administered with surfactants, stabilizers, and 
counter ions. The compositions of CPD and therapeutic peptide can be used to treat colon 
cancer, lung cancer, and several other cancers. This particular formulation is mainly suited 
for metastatic cancers of bladder, prostate etc.  This system may also be used in 
combination with other known therapies such as anti-arrhythmia agents, calcium channel 
blockers and alike. The compositions showed sustained release of therapeutic peptide over 
a period of 27 days to a month when tested in animal models.  
Shi et al.[96]described micro/nanoparticles having excellent stability and loading 
efficiency that can be encapsulated with multiple agents including targeting agents. The 
invention features particles that include an aqueous core, a first amphiphilic layer 
surrounding the aqueous core, and a polymeric matrix surrounding the first amphiphilic 
layer. These particles can further include a second amphiphilic layer surrounding the 
polymeric matrix. Any or all of the aqueous core(s), first amphiphilic layer, polymeric 
matrix, and optional second amphiphilic layer can include one or more active agents. The 
applicants have performed several in vivo studies (BALB/c nude mice) such as toxicity, 
tolerability studies and many other studies to determine the efficacy of the formulation.    
SeungPyo Hong[97]describe the use of amphiphilic dendron-coils (micelles) and 
their use for drug delivery and/or cell capture. Polymeric micelles are small, spherical 
particles (<200 nm in diameter) made up of polymer chains. The polymer chains of 
polymeric micelles are block copolymers (i.e., typically linear polymers composed of 
repeating blocks of two polymers that differ in hydrophilicity, charge or polarity). Some 
block copolymers that are amphiphilic block copolymers, which self-assemble into 
micelles when placed in an appropriate solvent. These self-assembled polymeric micelles 
represent one of the most assuring, complex platforms for delivery of drugs. The 
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nanostructural features, such as thermodynamic stability, size, and shape of self-
assemblies, can be widely manipulated depending on both amphiphilicity of materials and 
fabrication techniques. 
            Lipid-based Nanoparticles 
Mirkin et al.[98] came up with a nanoparticle composition comprising a 
polynucleotide-functionalized nanoparticle (PN-NP) and an embolic agent. The 
nanoparticle composition is useful for localized delivery to a site of pathogenesis, increased 
retention time, and genetic regulation. The composition described goes into the tumor cells 
without transfection agents and is resistant to degradation. This property of composition 
enhances knockdown activity compared to conventional polymer carriers. In addition, the 
embolic agent as described has shown to increase retention time of the composition at the 
desired site of delivery, thereby increasing effectiveness of the composition. The embolic 
agent has been selected from group consisting of lipid emulsion ( ethiodized oil and 
lipiodol) gelatin sponge, tris acetyl gelatin microspheres, embolization coils, ethanol, small 
molecule drugs, biodegradable microspheres, non-biodegradable microspheres or 
polymers, and self-assembling embolic material. Rabbit liver tumor model were utilized to 
compare the PN-NP uptake in tumors in conventional intravenous and intra-arterial 
delivery with and without an embolic agent. It was observed that nano-embolization 
increases PN-NP uptake and also minimizes their off-target distribution. 
Bisphosphonates (BPs) inhibits digestion of bone by encouraging osteoclasts to 
undergo apoptosis. Bisphosphonates can induce apoptosis by being fused metabolically 
into non-hydrolysable molecule similar to ATP. It has been reported that BPs can induce 
apoptosis and inhibit tumor cells growth for cancer cells in vitro 96.  BPs molecules have a 
tendency to accumulate in the bone as a result debilitating their use to treat extra-skeletal 
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tumors. Thus nanoformulation system that will limit accumulation of BPs in the bone and 
increase drug level in extra-skeletal sites is needed.  De Rosa et al [99], have described a 
class of self-assembly nanoparticles for release of bisphosphonates in treatment of human 
cancers. Self-assembly nanoparticles include bisphosphonate conjugated first to inorganic 
nanovectors and then conjugated to lipid nanovectors. Inorganic nanovectors can be 
particles of Zn, Ca, Mg, or Sr inorganic salts. Lipid nano-vectors are liposomes composed 
of sfingolipids and phospoglycerides. Formulation of self-assembly BPs nanoparticles may 
include PD or biological derivatives. Amount of BPs loaded in nanoparticles may be 
between 50μg-0.25 mg/ml of suspension. Nanovector (inorganic and lipid) may have a size 
range between 10-100s nm. Self-assembly nanoparticles can be used in treatment of 
different solid and hematological tumors. 
Lozano et al.[100] describe administering active pharmaceutical ingredients (API) 
using nanocapsule system with diameter less than 1μm. Nanocapsule system is a system 
that consists of a positive polyarginine, negative phospholipid, and oil.  Nanocapsule 
system is designed in such a way that, electrostatic interaction between positive 
polyarginine and negative phospholipid held the system together. Small size that 
nanocapsule offers, promotes transportation through different paths and mucosa. In 
addition, the positive surface charge from polyarginine will enhance biological surface 
interaction with negatively charged surfaces for instance tumor cells. In nanocapsule 
system, up to 50% by weight with respect to total weight in the system of active ingredient 
or excipient can be encapsulated. However, the amount of active ingredient varies with 
respect to their functions and intended use. Therefore, this system may be used to 
incorporate a wide range of components and different anti-cancer drugs. 
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             Magnetic Nanoparticles 
Jordan et al.[101] described composition consisting of coated nanoparticles used 
for transferring active therapeutic substances into cells particularly cancer cells. Material 
used to coat nanoparticles can either be positively polarized or positively ionized.  
Generally, coating material involves amino groups or a protonizable nitrogen atom which 
exists in protonized form at a corresponding pH. The particles are chemically designed in 
such a way that large amount of particles are absorbed into the cells without any 
requirement of direct bonds between nanoparticles and therapeutically active agents. This 
formulation showed an increase in efficacy and simultaneous reduction in systemic 
toxicity.  
An additional coating of biologically degradable polymers or biodegradable 
materials such as polyvalerolactone, poly-ε-decalactone, and polylactonic acid might be 
utilized. The additional biodegradable layer is either used to cover the positively charged 
layer or provide a coat which will not only compensate for the charge, but will also lead to 
an increment in cell discrimination. These nanoparticles might further be covered with a 
third coating that may play the role of a protective sheath, barrier layer or for cell 
discrimination purposes. The nanoparticles themselves may contain magnetic, 
ferromagnetic, or superparamagnetic material. 
Weaver et al [102]described a targeted drug delivery composition composed of 
carrier-linked magnetic nanoparticles. Using an alternating magnetic field, nanoparticles 
bound to a targeted cell are selectively ruptured thereby releasing therapeutic agents at the 
desired site of action. Composition of the invention consists of (a) first carrier-linked 
magnetic nanoparticle containing a PD and (b) a second carrier-linked magnetic 
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nanoparticle containing a moiety for activating the PD Both carrier-linked magnetic 
nanoparticles of (a) and (b) comprises of a targeting moiety. Magnetic nanoparticles may 
be composed of one or more magnetic elements such as iron, nickel, and cobalt as well as 
mixtures, composites, oxides or alloys thereof. Exemplary metals and alloys of use include 
Au, Ag, Pt, Cu, Gd, Zn, and many others. 
            Other Nanoformulations 
Kanwar et al.[103] described a method for producing a nanoparticle comprising 
calcium phosphate for delivery of an active agent. The nanoparticle can contain calcium 
phosphate core with an active agent absorbed onto the nanoparticle or an aqueous mixture 
of intestinal absorption enhancer like chitosan and calcium phosphate adsorbed with at 
least one active agent. This invention aims at ameliorating the problem of orally delivered 
drugs especially anti-cancer drugs that encounter harsh conditions of gastrointestinal tract 
by providing nanoparticles for delivery of an active agent. Applicants have demonstrated 
that mice fed with iron loaded lactoferrin adsorbed calcium phosphate nanoparticles did 
not develop any tumors. 
Radominska-Pandya and Biris [104]described a method for delivering anti-cancer 
nucleic acid into a pancreatic cancer cell. The anti-cancer nucleic acid may comprise of 
nucleic acid containing up to nine anti-cancer nucleic acids; nucleic acid encoding UGT, 
nucleic acid encoding p53, and any nucleic acids encoding tumor suppressor proteins. Anti-
cancer nucleic acid is attached to a carbon nanotube or any other nanocarriers may be used. 
The delivery system provides a method to ensure nucleic acid can still be expressed once 
delivered to cancer cells as the anti-cancer nucleic acid is delivered to the tumor site. 
Leuschner et al.[105] described a non-invasive in vivo technique for selectively 
delivering therapeutic agents to target cells such as tumors, metastases, micro-metastases, 
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and individual malignant cells. The covalent bonds between therapeutic molecules or 
ligands and magnetic nanoparticles are formed either directly or through a spacer molecule. 
Ligands used have high specificity for a target tumor cell receptor. The demand for a 
separate coating layer is ruled out by presence of a ligand such as hormone or antibody. 
The incorporation and specific accumulation of nanoparticles in targeted cancer cells via 
receptor mediated endocytosis enhances resolution for imaging, therapy or both. This 
invention might prove to be beneficial in high resolution, noninvasive in vivo imaging of 
tumors, and diseased joints to mention a few. This nanoformulation may also be useful in 
selectively destroying tumor cells or inflammatory cells. 
Adair et al.[106] have developed a diagnostic and treatment method by 
biconjugating calcium phosphosilicate nanoparticles (CPNPs) with chemotherapy, 
imaging, or gene therapy agents.  CPNPS serves as delivery system and protect 
chemotherapy, imaging, or gene therapy agents from physiological environment. CPNPs 
may be attached to a ligand, an antibody, or any other moiety that specifically recognizes 
and binds to a targeted tissue. In addition, CPNPs may be attached to imaging agents to 
bind to a target for diagnostic purposes. So far this method has been used for pancreatic 
cancer, breast cancer, and leukemia. 
Giacalone et al.[107] described the application of minicells (small, metabolically 
active copies of normal bacterial cells that do not contain any chromosomal DNA unlike 
normal cells) for the treatment of various cancer(s). These are genetically engineered 
eubacterial minicells that are designed to preferentially target and deliver therapeutically 
active agents. The conjugation of the minicells with therapeutic agents is done by using a 
minicell surface coupling molecule which is capable of binding antibodies and other Fc 
containing conjugates. The distinctive advantage of these minicells as delivery vehicles is 
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that they can engineered to target specific cell types in vivo for delivering large number 
and variety of bioactive molecules such as chemotherapeutic agents, proteins, nucleic acids 
etc. The compositions disclosed here in can be administered to any organism including 
animals and human by oral, rectal, parenteral or topical routes. 
Elisabet De Los Pinos and Rhonda Kines [108] have developed virion-derived 
nanospheres for selective delivery of therapeutic and diagnostic agents to cancer cells. 
Virion-derived protein nanosphere particles (NSPs) which display selectivity for delivering 
drug molecules to tumor cells without debilitating healthy cells and without producing 
serotype-specific immunogenic response, have been defined. These NSPs works by being 
attracted to properties that tumor and tumor cells exhibit. NSPs may contain anti-cancer 
drug, a therapeutic molecule, inorganic molecule, radioisotope, radiolabelled molecule, or 
biological molecules (siRNA, shRNA, DNA). As a result NSPs have a wide range of 
application as they may be used to selectively deliver therapeutic and diagnostic agents, in 
addition to anti-cancer drugs. 
Desimone et al.[109] has described the use of reversible linkers such as disulfide 
linker or reversible linker with trityl moiety, an ester moiety, or a CDM (carboxylated 
dimethyl maleic acid) moieties to deliver pharmaceutical, chemical and biological agents 
to their desired targets or areas. These reversible linkers can either be covalently bonded to 
therapeutic agents or can be contained in the delivery vehicles. Inventors proposed that 
these linkers can modify properties of agents and vehicles, thereby providing desired 
solubility, stability, hydrophobicity and targeting. The reversibility of the linker can leave 
the agent to which it is attached free from residual chemical groups after being reduced. 
This invention mainly focuses on the use of nanoparticles, liposomes, polymers and 
proteins for delivery of therapeutic agents.  
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Tao et al.[110]explained about combination therapy of taxane and hedgehog 
inhibitors encapsulated in nanoparticle. Taxane drugs such as paclitaxel and docataxel have 
shown anti-cancer effects in a number of cancers. In this formulation, nanoparticles are 
composed of paclitaxel, albumin carrier, and hedgehog inhibitor. Nanoparticles containing 
albumin carrier can be used as delivery system for hydrophobic drugs such as paclitaxel. 
Hedgehog inhibitor inhibits hedgehog signaling pathway which plays important role in 
pancreatic cancer once activated.  Paclitaxel together with hedgehog inhibitor encapsulated 
in albumin nanoparticles can be administered together or separately, but consecutively. 
These nanoparticles may treat advanced metastatic cancer, endocrine, and exocrine 
pancreatic cancers. 
1.11.3. Treatment of Disease:  Treatment of disease is another application of nanoparticle 
and closely related with the previous section. However due to the importance of this 
application, it requires a specific section. 
            Polymer-based Nanoparticles 
Stephen E. Zale[111] described the use of biocompatible polymers such as PLGA, 
PEG etc. in nanoparticles formulation. The invention is about designing targeted specific 
stealth nanoparticles (NPs) that have immensely high controlled release properties. The 
specific targeting can be to a particular tissue, cell type, or specific diseased tissue, but not 
normal healthy tissues. These NPs are formulated in such a way that they have a ratio of 
ligand-bound polymer to non-functionalized polymer effective for the treatment of prostate 
cancer. The non-functionalized polymer gives the nanoparticle “stealth” characteristics. 
The biocompatible polymeric nanoparticles may either be conjugated to a targeting moiety 
or it may contain a therapeutic agent. The formulation of such a target controlled release 
polymer systems is expected to reduce life threatening side effects of anticancer therapy. 
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This specificity property would also enable the therapeutic agent to reach the targeted 
tissues more efficiently. Various in vivo and in vitro studies have been proposed to achieve 
a desirable concentration range and perform other toxicity studies. The invention mainly 
focusses on preventing one or more symptoms of cancer particularly those expressed in 
prostate specific membrane antigen (PSMA). This system may also be used to treat 
glioblastoma, prostate cancer, non-small cell lung cancer, colorectal carcinoma, and solid 
tumors that express PSMA in the tumor neovasculature. 
            Lipid-based Nanoparticles 
De Rosa et al.[99] explained about nanocomplexes also called auto-assembling 
nanoparticles containing bisphosphonates complexed with inorganic and lipid nanovectors. 
In this formulation the bisphosphonate is first complexed to inorganic nanovectors and the 
resulting particles are then complexed to lipid nanovectors. Inorganic nanovectors consist 
of nanoparticles of a Ca-, Mg-, Sr- or Zn- inorganic salt. These nanocomplexes have shown 
to be efficient in vivo as pharmaceutical formulations of bisphosphonates for treatment or 
prevention of tumor growth and/or metastasis. Tumors can be solid hematological such as 
prostate, lung, head/neck, colon, liver, breast, pancreas, kidneys, bladder, male and female 
urogenital tract, bones, multiple myeloma, primitive and secondary tumors of the central 
nervous system and lymphomas.  
O’Halloran et al.[112]have explained the use of active forms of platinum and 
arsenic drugs into liposome for treatment and/or diagnostic of cancer. The liposome 
utilized to encapsulate platinum and arsenic compounds may contain target moiety and 
targeting ligand. The method claim to provide therapies for wide variety of cancers and 
cancer related illnesses including colon cancer, cervical cancer, bone cancer, bladder 
cancer, and acute myeloid leukemia to mention a few. 
26 
 
             Magnetic Nanoparticles 
Hong Zhu[113] described how targeted nanoparticle drug for magnetic 
hyperthermia can be used as a treatment method on malignant tumor.  The targeted 
nanoparticle drug can be magnetic nanoparticle-ligand targeted drug, magnetic 
nanoparticle-antibody targeted drug, or magnetic nanoparticle magnetic targeted drug. 
Magnetic nanoparticles can be made up of Fe2O3, Fe3O4, or any other super-paramagnetic 
nanoparticles of these molecules. Furthermore, magnetic nanoparticles can be conjugated 
to ligand or antibody. Surface modification can be done through coating, wrapping with 
organic or inorganic substances, and surfactants. Ratio of magnetic nanoparticles to 
antibody/ligand and the ratio of magnetic nanoparticles to surface modifying material to 
be 1: 0.0001-0.20. The size of magnetic nanoparticles can be between 2-1000nm, 
preferably less than 100nm for long circulation stability in the blood and improve 
permeability and retention in tumor site.  
Yangde Zhang[114] described magnetic nanoparticles that contain galactose 
albumin Adriamycin for treatment of liver cancer.  In this particular method cancer cells 
are targeted either passively or actively through incorporation of galactose on the surface 
of nanoparticles. This ensures high drug level delivered to liver cancer cells and less 
toxicity to healthy cells. So far this method has been used to treat hepatocarcinoma. 
            Metal-based Nanoparticles 
Xu et al.[115] described a nanoparticle of glucidamin derived from organism for 
treating tumor and the preparation method. Nano-class glucidamin can enhance the activity 
of nanoparticles against tumor. Particle diameter of glucidamin nanoparticle prepared by 
the method disclosed in the patent exhibits homogeneous distribution, meanwhile, the 
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nanoparticle is easy to be separated and purified from the emulsion. The nanoparticle of 
glucidamin is loaded with metal ions. 
            Other Nanoformulations 
Chun Li[116] describe the use of radiolabelled nanoparticles with a plurality of 
diagnostic and therapeutic functions. Usually radioisotopes are linked to NPs through 
chelators such as diethylene triamine pentaacetic acid, 1, 4, 7, 10 tetraazacyclododecane, 
or 1, 4, 7, 10-tetraacetic acid to form stable complexes. The present invention focuses on a 
novel inorganic nanoparticle, wherein the nanoparticle comprises of a metal radioisotope 
as an integral component of the nanoparticle thus obviating the issues of chelate instability, 
which was leading to accumulation of high radioactivity in non-targeted organs. In vivo 
distribution and accumulation of these nanoparticles in tumor sites can be confirmed non-
invasively by using nuclear imaging or near-infrared light. The inventors have also 
mentioned the use of transition metals as the core of nanoparticles. This technology can be 
used in treatment of variety of cancers such as melanoma, leukemia, ovarian, colon, 
prostate, lung, head, neck, and several other cancers. The radiolabeling efficiency and 
stability of labeled nanoparticles were determined using nude mice as animal models. 
Madiyalakan et al.[117] described nanoparticles and pharmaceutical compositions 
comprising a cancer therapeutic agent and methods for using them for drug delivery and 
sonodynamic or photodynamic treatment of cancer. These nanoparticles may be bound to 
a detectable labelling agent or a selective targeting moiety, such as an antibody (Ab) or an 
Ab fragment. This invention is directed to nanoparticles comprising of a hypocrellin B 
derivative which is susceptible to photo- or sonodynamic activation. These nanoparticles 
may be used as water-soluble drug for clinical applications including, but not limited to, 
intravenous injection or direct application to a tumor, for treatment of cancers. In vivo 
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photodynamic therapy was given to male balb/c mice to monitor the tumor response in 
terms of length, width and thickness. 
Manganaro and Rockwell[118] have established a method for treating cancer using 
ascorbate linked to nanocarriers containing anti-cancer active agent. This nanocarrier 
structure will release anti-cancer agent in presence of ROS. Nanocarrier may be polymer-
some or liposome and ROS may be hydrogen peroxide or superoxide. Ascorbate used in 
this composition is equivalent to sugars and can be oxidized to DHAA. Once oxidized, 
DHAA can be transported into cells through different glucose transporters which are found 
in every cell including cancer cells. High concentration levels of ascorbate in extracellular 
region can induce cancer cells death due to production of hydrogen peroxide. In addition, 
presence of extracellular hydrogen peroxide will result to increase ROS activities which 
can put tension and anxiety to tumor cells and cause cell damage. All these mechanisms 
together with the released anti-cancer agent should in one way or another is able to induce 
tumor cell death. 
Geroni[119] described a pharmaceutical composition where microspheres were 
incorporated with nemorubicin hydrochloride. These compositions are mainly used for 
chemo-embolization, particularly for loco regional treatment of tumors.  In particular, the 
present invention mainly relates to sulphonate-modified N-Fil hydrogel microspheres as 
preferred carrier on which loading nemorubicin hydrochloride. It was found that 
nemorubicin hydrochloride/microspheres formulation was more chemically stable than the 
active drug substance while administered as loco regional therapy and that the 
microspheres system exerts a protective effect towards the chemical stability of 
nemorubicin hydrochloride, thus allowing the release in a controlled and sustained matter 
exclusively of the active moiety.  
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Liangfang et al.[120] have defined a membrane encapsulated nanoparticle for 
diagnostic and treatment of gastrointestinal and stromal tumors. These nanoparticles 
consist of non-cellular material in the inner core and cellular membrane derived from a cell 
or membrane of a virus on the outer surface. The inner cellular core may contain material 
such as PLA, PGA, PLGA, and alike. The outer surface of nanoparticle may be made up 
of membrane derived from a unicellular or multicellular organism and occasionally a 
synthetic membrane. In some cases the outer surface may be from cells (WBC or RBC), 
platelets, immune cells (T cells, B-cells, macrophage), tumor cells, and cancer cells to 
mention a few. Nanoparticles that contain cellular membrane on the outer surface have 
shown to exhibit 2 to 5 times more half-life in blood circulation in vivo than PEG coated 
nanoparticles. 
Lebel-Binay et al.[121] from Bioalliance Pharma have developed nanoparticles 
loaded with chemotherapeutic antitumor drug for treating liver and gallbladder cancer. In 
this particular application, nanoparticles formulation comprise of at least one 
chemotherapeutic anti-tumor agent, poly (alkyl cyanoacrylate), and cyclodextrin. 
Concentration of chemotherapeutic agent may be between 0.01 to 200 mg/g, 0.1 to 70% 
w/w of cyclodextrin, and 1 to 25% w/w of poly (alkyl cyanoacrylate). Type of cancer that 
can be treated by this formulation may be solid tumor or hematopoietic tumor from 
hepatocellular carcinoma or any other type of cancer. 
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CHAPTER 2 
RATIONALE FOR INVESTIGATION 
            2.1. Overview 
Many first-line anticancer drugs are DNA-toxins or act on DNA associated 
enzymes. In order to elicit pharmacological response these drugs must localize in the 
nucleus in cytotoxic concentrations to intercalate with DNA or inhibit biosynthesis. For 
instance, only 5-10 % of the covalently bound cisplatin is found in DNA fraction, whereas, 
75-85% of the drug is bound to protein [122]. Hence, there is a need to develop an effective 
nuclear-targeted drug delivery. In this project two approaches have been followed. The first 
approach is PD modification of anti-cancer drug doxorubicin by conjugation of a small 
peptide. This approach may allow to evade efflux pumps which are over-expressed in 
cancer cells. Conjugation of the peptide to drug will allow it to be preferentially taken up 
by peptide transporters which are over-expressed in cancer cells.  Another approach is 
synthesis of modified NLS peptide sequences which have the potential to penetrate 
cytoplasm (both malignant and non-malignant) and localize in the nuclei. Direct nuclear-
drug delivery is challenged by hostile intracellular environment that present 
endo/lysosomal degradation as a major barrier. Modified NLS peptides can penetrate the 
plasma membrane of cancer cells, evading endo/lysosomal degradation and directly 
translocate across nucleopore membrane.  This hypothesis will be tested on four sets of 
cancerous cells and their non-malignant counterpart. Specific amino acid substitutions will 
be introduced in NLS sequence. Novel NLS peptides developed in this project may 
specifically localize in cancer cell nuclei but minimally penetrate non-malignant cell 
membrane. Once an optimum peptide has been created, it will be utilized to design a drug 
delivery system targeted to nuclei of cancer cells. 
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            2.2. Statement of Problem 
Drug delivery to nucleus is considered to be an important goal which has not been 
adequately addressed yet. This problem has been attempted to be addressed here. Barriers 
to drug delivery like efflux transporters which are expressed on the plasma membrane are 
also present on the nuclear membrane. A lot of work has been done to enhance cellular 
uptake of drugs. However not much effort has been made to enhance nuclear uptake of 
therapeutics. Many anti-cancer therapeutics have nucleus as site of action. Hence failure to 
reach nucleus prevents the drug from eliciting its pharmacological effect. This in turn leads 
to dose-escalation and dose related toxicity.  PD approach as mentioned in the previous 
section can be an effective strategy to address this issue.  
Another approach which has been investigated involves creation of novel NLS 
peptides. NLS peptides which are derived from Nuclear Localization Signal (NLS), can 
cause sequestration of chemotherapeutic cargo to nuclei of cancer cells. NLS peptide 
sequences have the potential to penetrate cytoplasm (both malignant and non-malignant) 
and localize in the nuclei. Hence there is a need to design novel NLS derived peptides that 
can selectively target cancer cells. Direct nuclear-drug delivery is challenged by hostile 
intracellular environment that include endo/lysosomal degradation [123].  It is 
hypothesized that modified NLS peptides can penetrate the plasma membrane of cancer 
cells, evading endo/lysosomal degradation and can directly translocate across nucleopore 
complex. This hypothesis will be tested with four sets of cancer cells and their non-
malignant counterparts. Specific amino acid substitutions based on hydrophobicity if 
introduced in NLS sequence it has the potential to enhance specificity of cancer cell nuclei. 
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However synthesis of cancer nuclei specific peptide is not adequate. A formulation of 
optimum size has to be developed. Nanoparticle formulation may be investigated for 
encapsulation of anti-cancer drug.  The optimized peptide may be conjugated on surface of 
the nanoparticle to create a targeted drug delivery system. Several methods are available 
for preparation of NP. Some of the widely used methods include solvent evaporation, 
salting out, nanoprecipitation, dialysis and supercritical fluid technology [124]. This work 
utilizes a nanoprecipitation method to create polymeric NP. Nanoprecipitation can be 
caused by solvent displacement method. A polymer is dissolved in a semi-polar organic 
phase which is miscible with water thereby causing deposition at the interphase of two 
phases, the other phase being an organic solvent [125] . As the organic solvent rapidly 
diffuses into aqueous phase interfacial tension between two phases is lowered. This process 
leads to enhancement in surface area producing small organic phase droplets. Because of 
this phenomenon nanoprecipitation small NP suitable for cancer drug delivery. It is less 
complicated than other techniques, consumes less energy and produces defined NP. 
Nanoprecipitation can be performed in two ways: i) dialysis method and ii) dropping 
technique [126].This study encompasses dropping method to prepare NP. Both PD and 
targeted nanoparticle approach need to be investigated in order to determine the better 
nuclear drug delivery strategy. 
             2.3. Objectives: 
1. To synthesize L-val-L-val-doxorubicin PD and test its efficacy in evasion of efflux pump 
2. To synthesize novel NLS peptides by solid phase peptide synthesis and purify them via 
preparative HPLC 
3. To determine uptake of synthesized peptides in various cancer and their corresponding 
non-malignant cells 
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4. To optimize various parameters with respect to size in order to design an optimized 
nanoparticle which can carry anti-cancer drug to its site of action. 
5. To conjugate peptide optimized objective 3 to the nanoparticle optimized in objective 4 
in order to determine its efficacy to deliver anti-cancer drug doxorubicin to the nucleus. 
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CHAPTER 3 
PRODRUG APPROACH FOR NUCLEAR DELIVERY OF DOXORUBICIN 
 
            3.1. Rationale 
Anthracyclins like doxorubicin have been widely used in chemotherapy[127]. The 
objective of this work is to design peptide transporter mediated delivery of doxorubicin 
which can accumulate in nuclei of cancer cells by evasion of efflux pumps. In this study 
two isoforms of PEPT-PEPT1 and PEPT2 have been selected as transporter. PEPT1 is a 
low-affinity, high-capacity transporter whereas PEPT2 is a high-affinity, low-capacity 
transporter24 .The PD developed in this work is L-val-L-val peptide conjugated to 
doxorubicin. L-val-L-val is an excellent substrate of both PepT1 and PepT2 which are 
overexpressed in plasma and nuclear membranes of cancer cells.  
This study provides proof-of-concept that PD modification of doxorubicin can 
enhance its exposure to tumor cells and reduce dose-related toxicity. This approach may i) 
evade efflux transporters since the parent drug is a substrate of efflux pumps but not the 
PD. ii) The peptide PD (val-val-doxorubicin) will be recognized by peptide transporters 
highly expressed on both plasma and nuclear membranes of tumor cells. Once inside 
nucleus the PD will be cleaved to its parent drug doxorubicin. This dual approach may 
significantly enhance drug efficacy and reduce dose required to achieve pharmacological 
action (Fig.1). 
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Fig.1: Translocation of pro-drug across plasma and nuclear 
membrane of breast cancer cells 
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           3.2. Materials and Methods 
            Materials:  
T-47D (breast cancer cell line) was obtained from ATCC. Glysar, cefadoxil, 
cephradine, PGP-4008, MK-571 and doxorubicin were purchased from Sigma-Aldrich, 
USA. GF-120918 was obtained from glaxoSmithKline, USA. 
 FMoc-Val-Val was purchased from Fisher-scientific. Diisopropylethylamine 
(DIEA), DMF, dichloromethane and diethyl ether and o-benzotriazol-N,N,N1,N1 –
tetramethyl –uronium hexafluoro-phosphate (HBTU) were obtained from Sigma-
Aldrich,USA. Piperidine was purchased from Fisher scientific, USA. 
            Methods: 
            Cell Culture Method 
Breast cancer cell line, T47D cells, of passage numbers (20–25) was selected for 
studies. Cells were cultured in 75 mL flasks (T-75). Cells were grown at 37° C in a 
humidified atmosphere with 5% CO2. Nutrient medium to maintain cells consisted of 
DMEM medium at pH 7.4 supplemented with 10% FBS (heat inactivated), 1% 
nonessential amino acids, 20 mM HEPES, 29 mM sodium bicarbonate and 100 μg/mL of 
penicillin and streptomycin each. pH of medium was adjusted to 7.4. The medium was 
replaced every alternate day to ensure proper growth. Cells were allowed to reach 80–90% 
confluency and then passaged with TrypLE™ Express solution. Cells were seeded at a 
density of 250,000 cells/well in 12-well tissue culture-treated plastic plates and then 
allowed to grow for 5–7 days. These cells were subsequently utilized for further studies. 
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            Uptake Studies  
Uptake studies were performed using 12-well plates according to established 
protocol31 with minor modifications. After 6-8 days of seeding, confluent T-47 D cell 
monolayers were rinsed three times with DPBS buffer (pH 7.4). Uptake was initiated by 
the addition of 1 mL drug solution containing 0.5μCi/ml [3H] Gly-Sar on apical side. 
Experiments were performed in presence or absence of competing substrates and 
inhibitors. Incubation was carried out over a period of 30 minutes. Following incubation, 
cell monolayers were rinsed three times with ice-cold solution (200 mM KCl and 2 mM 
HEPES) to terminate drug uptake. Cells were lysed overnight using 1mL 0.1% (wt/vol) 
Triton X-100 in 0.3N sodium hydroxide at room temperature. Aliquots (500μL) were 
withdrawn from each well and transferred to scintillation vials containing 5mL scintillation 
cocktail. Samples were then analyzed by liquid scintillation spectrophotometry with a 
Beckman scintillation counter (Model LS-6500, Beckman Instruments, Inc.). Uptake data 
was normalized to the protein content of each well. Amount of protein in the cell lysate 
was quantified by the Bradford method utilizing BioRad protein estimation kit (BioRad, 
Hercules, CA). 
            Nuclear Isolation 
 Isolation of nucleus from T-47 D cells was performed based on the principle of 
cell fractionation and differential centrifugation. Briefly, confluent T47D cells were grown 
in 150 cm2 flask were harvested by trypsinization, washed two times with ice-cold PBS. 
The pellet was generated at 4° C, centrifuged at 8000 RPM for 10 min. The Resulting pellet 
was re-suspended in 500 mL of ice-cold homogenization buffer (0.25 M sucrose, 1 
mMEDTA, 10 mM HEPES; pH 7.4) and incubated on ice for 10 min. Following 
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incubation, cells were homogenized with pre-chilled dounce homogenizer (40 to 50 
strokes) and cell lysis was ensured by lactate dehydrogenanse assay. The resulting 
homogenate contained the nuclear fraction, which was transferred into 10 mL centrifuge 
tube by making volume up to 5 mL with homogenization buffer and centrifuged at low 
speed (1000 g, 10 min, 4° C) to remove unlysed cells.  
            Synthesis of Doxorubicin PD 
Val-Val-Doxorubicin PD was synthesized by solution phase method. DIEA (N, N-
Diisopropyl ethylamine) in dimethylformamide (DMF) was selected as a coupling reagent. 
A mixture of DOX and DIEA (1:2 equivalents) in dry DMF was stirred for 10 minutes 
under nitrogen atmosphere at room temperature in dark. Following stirring of DOX and 
DIEA, FMoc-Val-Val and HBTU [1:1 equivalent] in DMF were added to the solution and 
stirred for 4.5 hours at room temperature.  Solvent was evaporated overnight under high 
vacuum. Fmoc-val-val DOX was treated with 20% piperidine in DMF for 20 minutes at 
0oC. The obtained amide bond doxorubicin peptide PD residue was co-evaporated with 
dichloromethane (DCM). The final product, dipeptide –DOX dark red flakes, was purified 
by crystallization with cold diethyl ether (Fig.2). Following synthesis the purified product 
was characterizd mass spectromentry. Its m/z value is 742.7. 
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Fig.2: synthetic scheme of dipeptide valine-valine PD of doxorubicin 
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PD Characterization Mass Spectrometer: 
 The mass of the final purified product was identified by a mass spectrometer (MDS 
Sciex API 2000 Triple Quadrupole linier QTrap mass spectrometry, Applied 
Biosystems/MDS Sciex, Faster City, CA). The system was interfaced with turbo ion spray 
(TIS) in positive ion source for detection.  A constant flow rate of 15 µl/min was infused 
into mass spectrometer. 
            HPLC Method: 
In vitro analyses of doxorubicin and its peptide PD were performed by a reversed 
phase high performance liquid chromatography (RP-HPLC) method with a Waters 515 
HPLC pump (Waters corporation, Milford, M.A), Alcott autosampler (model 718 AL), 
Agilent 1100 series fluorescence detector, Zorbax SB-phenyl column (5 um, 25 x 4.6 mm) 
(Agilent technologies, Santa Clara, CA), and Hewlett Packard HPLC integrator (Hewlett 
Packard, Palo Alto, CA). The mobile phase was comprised of 65% of 10mM phosphate 
buffer as aqueous phase and 35% acetonitrile as organic phase which was pumped at a flow 
rate of 1.2 mL/min. Detection wavelength was set at emission and excitation of 480 nm 
and 560 nm, respectively. Calibration curve (0.5 to 5.0 µg/mL) for doxorubicin was 
prepared by making appropriate dilution from the stock solution.  An injection volume of 
50 µl was injected into the HPLC column for analysis. A calibration curve with a regression 
coefficient of 0.995 was prepared.  The other HPLC parameters are provided in table 1 
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Table 1: HPLC parameters for determination of PD stability 
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            Stability Studies: 
Preparation of T-47D Cell Homogenate:  
Confluent T-47D cells grown in tissue culture flasks were isolated with the aid of 
mechanical scraper and washed three times with Dulbecco’s phosphate-buffered saline 
(DPBS). Cells were homogenized in 2 ml of chilled (4°C) DPBS for about 10 min with a 
mechanical homogenizer in an ice bath. Subsequently, the homogenates were centrifuged 
at 12,500 rpm for 25 min at 4°C to remove cell debris, and the supernatant was subjected 
to stability studies. 
 Stability Studies:  
Supernatant obtained from T-47D cells as described previously was equilibrated at 
37°C for about 15 min prior to an experiment. Supernatant (0.8 ml) was incubated with 0.2 
ml of 1 mM PD solution at 37°C in a shaking water bath for the entire study period. Positive 
control consisted of 0.8 ml of DPBS instead of supernatant. Aliquots (50 μl) were 
withdrawn at appropriate time intervals over 24 hours. The samples were immediately 
diluted with 50 μl of chilled acetonitrile/methanol (4:5 mixture) to precipitate the proteins 
and the supernatant was stored at −80°C until further analysis. The protein content of the 
supernatant was determined by the method of Bradford (1976) (Bradford, 1976) using 
bovine serum albumin as the standard (protein estimation kit; Bio-Rad, Hercules, CA). 
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             Statistical Analysis: 
All experiments were conducted at least in triplicate and results are expressed as 
mean ± S.D. Student’s t test was applied to detect statistical significance between the 
parameters  and p<0.05 was considered to be statistically significant. 
            3.3. Results and Discussions: 
The purified product resulted in 56% yield with a purity of >95 % as determined 
by HPLC. Val-Val-doxorubicin PD was characterized with mass spectroscopy.  Mass 
spectrometer indicated the peptide doxorubicin PD peak at 742.7 amu. 
            Stability Studies:  
The stability data show that peptide conjugate of doxorubicin is metabolically more 
stable in T-47D cell homogenate (≈ 5% degradation of L-Val-L-Val DXR in 12 hrs). This 
will allow sufficient time for the PD to be recognized by peptide transporter present on 
nuclear membrane.  Hence nuclear targeting becomes a possibility. It is a promising 
strategy since the PD can provide sustained and targeted delivery of doxorubicin (Fig. 3).  
The stability of the PD is due to amide bond conjugating valine and doxorubicin. Therefore, 
it prevents the peptide moiety (Val-Val) cleavage outside the cell membrane. 
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Fig.3: stability data of doxorubicin PD in T-47 D cell homogenate 
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            Expression of Efflux Pumps and Interaction with Peptide PD 
Expression of efflux pumps in breast cancer cells was evaluated utilizing various 
inhibitors which suppress activity of efflux transporters. Uptake of [14C] erythromycin was 
performed in the presence of various inhibitors of P-gp and MRP.  PGP-4008, a specific 
inhibitor for P-gp, GF-120918, a dual inhibitor for both P-gp and BCRP and MK-571 and 
inhibitor of MRP are selected to determine the specificity of the PD Moreover excess 
doxorubicin was also included as competitive substrate inhibitor for the transporters. 
Erythromycin is a substrate for both P-gp and MRP. Uptake of 14C-Erythromycin was 
elevated 2.5 fold in response to PGP-4008 in BCC monolayers. This result suggests 
expression of P-gp in these cells. Similarly 14C-Erythromycin uptake was enhanced by 
almost 5-fold in presence of MK-571. This data indicates inhibition of MRP in this process. 
The result indicates high expression of MRP in T-47D cells. Surprisingly GF-120918 
caused insignificant enhancement of erythromycin uptake compared to positive control 
(14C-Erythromycin in absence of any inhibitor). GF-120918 is a strong inhibitor of BCRP 
and weak inhibitor of P-gp. Hence it is evident from this result that erythromycin is not a 
substrate of BCRP. Also, addition of unlabeled doxorubicin elevated uptake of 14C-
Erythromycin by almost 4.5 fold. It may be due to competitive substrate inhibition of both 
P-gp and MRP. From these experiments it becomes clear that doxorubicin is a substrate of 
efflux transporters while the PD L-val-L-val-doxorubicin is not a substrate. One of the 
reasons for low bioavailability of doxorubicin in cancer patients is possibly due to drug 
efflux. Hence higher doses are required for therapeutic efficacy which leads to dose-related 
toxicity. If this form of resistance development can be prevented it will lead to a much 
better therapeutic outcome. From Fig.4 it is apparent that the PD derivatization of 
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doxorubicin may achieve that goal. The peptide PD can bypass the efflux pumps and 
therefore may be able to reduce dose-related toxicity.  
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.4: Uptake of [14C] erythromycin in presence of various efflux 
pump inhibitors, doxorubicin and its PD 
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            Peptide Transporter (PEPT) on Plasma Membrane of BCC: 
 Gly-sar is a model substrate of human peptide transporter. Cephradine and 
Cefadroxil are inhibitors of PEPT1 and PEPT2 respectively. Uptake of [3H] gly-sar was 
measured in presence of 1mM gly-sar, 1mM Cephradine, 1 mM cefadroxil. This study 
suggests that there is indeed an inhibition of [3H] gly-sar uptake in the presence of 
unlabeled gly-sar and PEPT inhibitors. Unlabeled gly-sar is a substrate of both PEPT1 and 
PEPT2. Hence the peptide PD competes with [3H] gly-sar resulting in almost 50% decrease 
in uptake of [3H] gly-sar. In the presence of both cephradine and cefadroxil there is 
approximately 25% inhibition in the uptake of [3H] gly-sar. These results clearly indicate 
the expression of both PEPT1 and PEPT2 on plasma membrane of BCC (Fig.5). Hence, 
these transporters may offer an attractive target for the development of PD which may 
enhance accumulation of doxorubicin in cancer cells. 
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Fig.5: Uptake of [3H] glysar in the presence of unlabeled glysar, 
cephalosporins in T-47D showing presence of PEPT1 and 2 (n=3) 
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             PEPT on  Nuclear Membrane: 
 Experiments have been performed to show  presence of peptide transporter on  
nuclear membrane of  T-47 D . our studies indicate that in presence of unlabelled glysar, 
nuclear uptake of [3H] gly-sar is competitively inhibited (Fig.6). In presence of unlabelled 
gly-sar (2.5mM) uptake of [3H] gly-sar decreases approximately 1.8 times. This study 
suggests that nuclear membrane of T-47D cells express peptide transporters. This may be 
exploited for targeted drug delivery. Peptide transporters might be able to translocate our 
peptide PD ino the nucleus. This has the potential to enhance bioavailability and reduce 
dose related toxicity. 
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Fig.6: Nuclear uptake of [3H] glysar in presence of unlabeled glysar 
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            In-vitro efficacy of PD 
Fig.7 depicts approximately tenfold elevated accumulation of Peptide-PD of 
doxorubicin (L-Val-L-Val-DOX) compared to parent drug DOX in T-47D cells. Therefore 
PD of anticancer agents targeted to hPEPT may undergo facilitated transport into 
cytoplasm as well as nucleus of BCC. This result indicate that the may exert more potent 
anticancer activity than the parent drug doxorubicin. 
 
 
 
 
 
 
 
 
Fig.7: Uptake of Dox and L-val-L-val-Dox in T-47D cells 
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Chemotherapeutic agents like doxorubicin which are mostly administered 
systemically exhibit limited permeability into BCC. Efflux pumps like P-gp and MRP are 
responsible for poor uptake of various chemotherapeutic agents. Inability of drugs to evade 
efflux may be one of the major impediment to cancer chemotherapy. Cancer cells exhibit 
higher expression of efflux pumps relative to normal non-malignant cells. Most cancer 
drugs like doxorubicin are substrates of efflux transporters like P-glycoprotein, MRP and 
BCRP.  
 Cyclosporine has been included in cancer treatment regimen as a P-gp inhibitor by 
a few studies [128]. It was anticipated that anticancer agents would show better efficacy. 
However this approach has not been very successful. For therapy to be effective, cancer 
cells should be exposed to chemotherapeutic agents in therapeutic concentrations. Usually 
intravenous route is preferred for administration of chemotherapeutic agents. As a result 
normal cells are exposed to a high concentration of anticancer agents resulting in 
cytotoxicity[129]. Also, exposure to chemotherapeutics causes up regulation of multidrug 
resistant (MDR) genes. It may enhance expression of efflux pumps (P-gp, MRP and BCRP) 
leading to elevated drug efflux out of cancer cells23.Most chemotherapeutics are excellent 
substrates of efflux pumps.  
Failure of chemotherapeutics to elicit pharmacological response in cancer patients 
may be caused by presence and/or development of drug resistance. The present study 
shows this issue can possibly be resolved by PD derivatization. The peptide PD synthesized 
is not a substrate of the efflux transporters as evident from fig.4. However it is a substrate 
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of the influx peptide transporters expressed both on the cell membrane and the nuclear 
membrane (Figs.6 and 7). Hence there is a higher probability of accumulation of the 
chemotherapeutic agent inside the cancer cell nuclei. Our data provide evidence of hPEPT 
expression on plasma and nuclear membranes of T-47D breast cancer cells (Figs.6 and 7). 
Inhibition of [3H] Gly-Sar (preferred substrate for hPEPT) uptake by unlabeled Gly-Sar 
and cephalosporins indicates expression of specific hPEPT on BC cells.  Enzymatic 
hydrolysis will follow to generate parent drug. Of importance is ability of drug peptide 
conjugate to overcome drug efflux pumps at both cell and nuclear membranes (Figs.6 and 
7). The data clearly provides evidence that peptide conjugate of DOX can bypass efflux 
pumps. Since nucleus also express efflux pumps, PD of DOX may also bypass efflux at 
nuclear membrane. This strategy may be suitable for targeting both plasma and nuclear 
membranes of BC cells thereby enhancing anticancer efficacy at target organ. 
Another interesting property of the synthesized PD is its stability. As Fig.7 shows 
this PD is highly stable. Hence the PD may not readily revert back to the parent drug in the 
cytoplasm. It would allow the PD sufficient time to enter the nucleus. If the drug is not 
stable and conversion of the PD to drug occurs even in cytoplasm, there is a possibility that 
the parent drug will be effluxed out. Hence a stable PD like val-val-doxorubicin has the 
potential to enhance availability of the chemotherapeutic agent in tumor cells. 
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            3.4. Conclusion 
 Peptide PD derivatization has the potential to deliver anticancer drugs effectively 
into nucleus of cancer cells. As a result its therapeutic activity is enhanced. Hence this 
approach needs to be developed as an effective cancer treatment. However the PD is 
extremely stable and do not biorevertto the parent drug in therapeutic concentration. This 
is due to the strong amide bond between the L-val-L-val promoiety and the parent drug 
doxorubicin. Hence this strategy is not pursued further for this dissertation project. 
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CHAPTER 4: 
NLS PEPTIDE SYNTHESIS AND PURIFICATION 
 
            4.1. Rationale 
For cargo to cross nuclear membranes it needs to carry NLS sequence to interact 
with importin in order to facilitate translocation across nuclear membrane. One such 
peptide is adenoviral fiber protein, which is capable of evading endosomal degradation 
[130]. NLS peptides have the potential to deliver nanocarriers into nucleus. Little is known 
about the structural requirements of these peptides to interact with importin α/β. Specificity 
of these peptides for different cell types (malignant and nonmalignant cells) have not been 
investigated so far. Consequently, NLS peptides may be nonspecific and may translocate 
nano-carriers in both tumor as well as normal cells with equal efficiency.  NLS peptide 
analogues will be prepared based on hydrophobic modification (table 2). Hydrophobic 
interactions have been reported to be dominant for interaction with importins[131]. 
Hydrophobic interaction is proportional to the surface area of interacting molecules. An 
increase in surface area is likely to strengthen the interaction. Therefore amino acids with 
hydrophobic side chains will be replaced with valine, which possesses a more hydrophobic 
side chain. Valine was selected based on the hydrophobicity scale published by Kyte J and 
Doolittle RF [132]. The native peptide which has been selected is a component of 
adenoviral fiber protein which has both CPP and NLS components. CPP is necessary for 
endosomal escape. Modifications will only be introduced in the NLS component of the 
peptide as shown in table 2. Also, in order to analyze specificity of the novel peptides, these 
must be synthesized and purified. This chapter discusses synthesis and purification of these 
NLS peptides. 
 
56 
 
 
 
 
 
 
 
 
 
          
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Table 2: Native and modified peptides 
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            4.2. Materials and Methods 
            Materials: 
Peptide synthesizer, amino acids and resins were purchased from AAPTECH Inc. 
Preparative HPLC was purchased from Shimadzu corporation and LC-MSMS was 
purchased from Applied Biosystems/MDS Sciex, Faster City, CA. chemicals and solvents 
like piperadine, DMF, acetonitrile, HBTU, DIEA were purchased from Thermofisher 
scientific. 
           1. Synthesis of Peptides: 
In solid phase peptide synthesis (Fig.8), the peptide is prepared in a stepwise 
fashion from C-terminal of the peptide. The first amino acid which constitutes C-terminus 
is attached to the peptide synthesis resin. This procedure for preparing a peptide 
utilizes Fmoc-amino acids, HBTU and pre-loaded Wang resin.   
            Weighing and Swelling the Resin 
100 mg of wang resin is weighed into reaction vessel.  N, N-
dimethylformamide (DMF, approximately 10 mL/gram of resin) is added into the reaction 
vessel.   The mixture is allowed to stand at room temperature for fifteen minutes. This 
would lead to swelling of resin beads. DMF is drained after swelling of resin is complete. 
            Deprotection and Coupling 
1.  Fmoc-protecting group using the standard Fmoc deprotection protocol. 
2. Next amino acid is preactivated and coupled in sequence using 
standard HBTU procedures. Test for completion of the coupling step using the Kasier 
(ninhydrin) test.  Deprotection and coupling steps are repeated until the peptide sequence 
is completed. 
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Fig.8: Solid phase peptide synthesis [134] 
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            Cleaving the Peptide from Resin 
Cleaving the peptide from Wang resin or Rink Amide resin also removes the 
protection group from the side-chains of the peptide.  To prevent byproducts of 
deprotection and cleavage from reacting with the peptide and forming undesired impurities, 
scavengers are added. N-terminal Fmoc protecting group is removed using standard Fmoc 
removal procedures. 
1.  Resin is washed at least 3 times with DMF to remove all piperidine. Wash 
the resin at least 3 times with DCM to remove the DMF.  Residual DMF can make isolation 
of the crude cleaved peptide difficult. 
2. Peptide is cleaved from resin and isolated. 
            Purification of Peptides:  
Purification of peptides was performed with a shimadzu preparative HPLC and 
analyzed by diode array detector couple with LC/MSMS. 
            Preparative HPLC Assay 
 Peptides are purified by a shimadzu (Shimadzu Scientific Instruments, Columbia, 
MD, USA) preparative HPLC system. Phenomenax preparative column (Phenomenex C18 
kinetex column 100X4.6 mm, 5μm) along with a guard column (Phenomenex SecuritGuard 
Catridges, C18, 4x2 mm) was used with a flow rate of 0.5 mL/min. A gradient elution 
method was employed for separation where mobile Phase A (HPCL water (Sigma) with 
0.1% formic acid) at 10% and mobile phase B (ACN with 0.1% formic acid) at 90% were 
ran for first 2 min followed by a linear gradient to reach 100% phase B at 18 min. eluent 
containing the desired peptide fraction was collected at specific time points. 
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            HPLC-MS analysis 
HPLC-MS was performed using electrospray ionization (ESI) in positive ion mode 
on a QTrap® API-3200 mass spectrometer, equipped with Shimadzu quaternary pump, 
vacuum degasser, DAD detector and autosampler (Shimadzu Scientific Instruments, 
Columbia, MD, USA). Data acquisition and data processing performed using Analyst 1.4.2 
software package (Applied Biosystems, Foster City, CA, USA). LC conditions including 
column and gradient composition remains same as explained in the previous section. 
Injection volumes were 30 μL for all samples. UV detector was set on 280 nm and MS was 
set in range of 200 to 1700 amu. Total ion chromatogram was extracted for purified peptide 
m/z to produce extracted ion chromatogram and compared with UV chromatogram to 
identify purified peptide. 
 
            Cytotoxicity Assay: 
 Cytotoxicity was carried out with Cell Titer 96® Aqueous Non-Radioactive cell 
Proliferation Assay Kit (Promega, Madison, WI) to test the toxicity of all the peptides. 
D407 were grown on 96 well plates. Aliquots (100 μL) of sterile peptide solutions (100 
μM) in culture medium were added to each well and incubated for 48 hours. Cell 
proliferation in the presence of peptides was compared with control media. Following 24 
hours of incubation, 20 μL of freshly prepared tetrazolium dye solution (following 
manufacture’s protocol) was added to each well. The dye was allowed to incubate for two 
and half hours enabling the dye to react. The amount of formazan formed was measured 
using a 96-well micro titer plate reader (SpectraFluor Plus, Tecan, Maennedorf, 
Switzerland), absorbance set at 490 nm wavelength. Cytotoxicity measurements were 
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estimated by the amount of formazan formed which is directly dependent on the cell 
viability. 
            Gel Electrophoresis: 
To further investigate purity of NLS peptides sodium dodecyl sulphate-
polyacrylamide gel electrophoresis (SDS-PAGE) was performed as per previously 
published protocol (Panyam et al., 2003). Briefly, peptide samples were mixed with 
Laemelli's buffer and boiled for 5 min. Following this a 20 μL aliquot of the mixture was 
loaded onto wells of a pre-cast NuPAGE 4–12% w/v Bis-Tris gel (Invitrogen, Carlsbad, 
CA). The samples were then subjected to electrophoresis at 60V. A blue silver staining was 
employed for protein visualization [133]. 
               4.3. Results and Discussion: 
Table 3 depicts the different m/z values of the five purified peptides.  The molecular 
weight of synthesized peptides range from 3000 to 3500. However maximum molecular 
weight the LC-MSMS can detect is 1700 amu. Therefore it is necessary to detect m/z values 
of ionic fragments of peptides to determine successful purification of NLS peptides. Fig.9 
shows elution time of NLS1 and Fig.10 represents UV and MS spectra of NLS1 fragments. 
The elution time is 16.77. Fig.10 depicts +5 and +6 fragments of NLS 1. Fig.11 shows 
elution time of NLS2 and Fig.12 represents UV and MS spectra of NLS 2 fragments. The 
elution time is 16.77. Fig.12 depicts +5 and +8 fragments of NLS2. Fig.13 shows elution 
time of NLS3 and Fig.14 represents UV and MS spectra of NLS 3 fragments. The elution 
time is 17.29. Fig.14 depicts +5 and +6 fragments of NLS 3. Fig.15 shows elution time of 
NLS 4 and Fig.16 represents UV and MS spectra of NLS 4 fragments. The elution time is 
16.07. Fig.16 depicts +4 and +6 fragments. Fig.17 shows elution time of NLS5 and Fig.18 
represents UV and MS spectra of NLS 5 fragments. The elution time is 17.18. Fig.18 
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depicts +4 and +8 fragments. Similar results were obtained with Gel electrophoresis. Single 
band was obtained around 3 kD in each lane with no other fragment observed (Fig.19). It 
was also observed from MTT assay that the peptides were not toxic to normal cells 
(Fig.20). Percentage cell viability of the peptides are almost similar to control. These 
peptides are safe to be utilized as targeting moieties for drug delivery systems. Hence five 
peptides were successfully synthesized and purified for further experiments.  
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Table 3: m/Z values of NLS peptides 
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Fig.9: Chromatogram showing elution of NLS 1 
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Fig.10: UV and MS spectra of purified fraction of NLS 1 
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Fig.11: Chromatogram showing elution of NLS 2 
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Fig.12: UV and MS spectra of purified fraction of NLS 2 
+5 
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Fig.13: Chromatogram showing elution of NLS 3 
69 
 
 
 
 
 
 
 
 
 
Fig.14: UV and MS spectra of purified fraction of NLS 3 
+5 
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Fig.15: Chromatogram showing elution of NLS 4 
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+4 
Fig.16: UV and MS spectra of purified fraction of NLS 4 
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Fig.17: Chromatogram showing elution of NLS 5 
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Fig.18: UV and MS spectra of purified fraction of NLS 5 
+4 
+8 
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Fig.19: SDS page of purified peptides 
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Fig.20: MTT assay of purified peptides in D407 cells 
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            4.4. Conclusion: 
Novel NLS peptides were successfully synthesized and purified for further 
experiments. It was essential to purify the peptides as during synthesis different fragments 
are generated besides the desired product. These fragments negatively affect the activity 
profile of NLS peptides. 
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CHAPTER 5 
 
UPTAKE OF SYNTHESIZED PEPTIDES IN DIFFERENT CELL LINES 
 
            5.1. Rationale: 
The primary objective of this study is to design novel nuclear localization signal 
(NLS) peptide analogues that can carry therapeutic molecules specifically into nucleus of 
cancer cells. This strategy can reduce toxicity to healthy cells by delivering anticancer 
drugs to subcellular organelle i.e. nucleus of cancer cells preferentially. Native NLS 
peptide-conjugated therapeutics are able reach nuclei of any cells non-specifically. 
Adenoviral Fiber Protein (AFP) that contains NLS has been known to penetrate both 
plasma and nuclear membranes nonspecifically[134]. However novel NLS peptides 
synthesized in the previous section are expected to be specific to cancer cell nuclei.  This 
chapter investigates and screens the peptides designed in the previous section for its 
specificity towards cancer cell nuclei. 
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            5.2. Materials and Methods: 
 
            Material: 
     Fluorescein Isothiocyanate (FITC) was purchased from sigma-aldrich 
Corporation. All the cell lines were obtained from American Type Culture Collection 
(ATCC). ). Experiments were performed in passages two to six of cells sub-cultured from 
a frozen vial. Cells were grown in Dulbecco’s modified Eagle’s medium/F12 (50:50) 
media, RPMI media and Dulbecco’s modified Eagle’s medium (Mediatech, Herndon,VA) 
at 37°C in 5% CO2 environment. 
 
Labeling of Peptides with FITC-fluorescein isothiocyanate (FITC) Labeling was 
conducted similar to the protocol described by Lane et al (Harlow, E., and Lane, D. (1988) 
Antibodies: A Laboratory Manual, p. 354, Cold Spring Harbor Laboratory, Cold Spring 
Harbor, NY). FITC was dissolved in DMSO to a concentration of 1 mg/ml, and added to 2 
mg/ml of NLS 1-5 in 50 mM potassium phosphate buffer (final pH 7.6). The final 
concentrations of the solutions were adjusted to 25 mg/ml. The calculated molar ratio of   
FITC to the 5 NLS were observed to be approximately 0.10. After incubation for 16 hour 
in the dark at 4 °C, 50 mM NH4Cl was added to inactivate the residual TRITC or FITC. 
The solution was left in the dark for an additional 2 h at 4 °C, and stored in aliquots at -20 
°C. Labeling experiments were carried out in 1 mM phosphate-buffered saline (PBS) 
containing 9 mM K2HPO4/KH2PO4, pH 7.0, in 150 mM NaCl. Purification of the peptides 
was carried out using dialysis. 
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            Uptake Studies: 
            Nuclear Extraction 
Similar protocols were followed to perform uptake of peptides into nucleus of Y-
79 and D-407. Slight difference in method is due to non-adherent character of y-79 cells. 
Approximately 100,000 cells per well were plated onto 12-well plates 2 days prior to the 
experiment (y-79 cells were grown in flasks instead of 12-well plates) and cells were 
allowed to reach confluence. The cells were then washed with two 1 mL washes of 
Phosphate Buffer Saline, after which they were exposed to 300 µL of 10 µM FITC labelled 
peptides in serum free media for 30 minutes. The cells were then washed with two 1 mL 
washes of PBS, and lightly trypsinated to remove any external peptides that may have been 
attached to the cellular membrane and facilitate the detachment of cells from the 12-well 
plate/ flask. The cells were transferred to 15 ml tubes for nuclear extraction and lysis for 
analysis and quantitation of nuclear entry of the peptides. 
            Confocal Studies:  
In vitro uptake of 500 nmol of different NLS peptides tagged with FITC were 
analyzed in different cancer and non-malignant cell lines for 45 minutes. Following 
incubation, cells were washed with cold DPBS, stained with cell mask plasma membrane 
stain, fixed and counter stained with DAPI nuclear stain. A series of images were acquired 
in the z-axis (0.5 µm apart) with confocal laser scanning unit. A Leica TCS-SP5 WLL 
inverted system equipped with AOBS, white light laser (enables 200 excitation laser lines, 
tandem scanner, excitation scan and dye separation in the range of 470-670nm), an Argon 
laser, a 405 laser, 5 spectral detectors and a transmitted light PMT equipped with 
environmental controls, employed for  cell imaging. Proprietary Leica confocal microscope 
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imaging software for quantitative data acquisition and analysis are utilized. Co-localization 
studies was performed with image J software.  
            Pearson’s Coefficient: 
The Pearson product-moment correlation coefficient   is a measure of linear 
correlation between two variables X and Y, giving a value between +1 and −1 inclusive, 
where 1 is total positive correlation, 0 is no correlation. It can be applied for quantification 
of colocalization of fluorophores in confocal images. It is assumed if the value of Pearson’s 
coefficient is more than 0.5 colocalization exists.  In order to remove background noise, 
costes’ threshold has been applied to images before Pearson’s coefficient is calculated. 
Mathematically Pearson’s coefficient r with fluorophores x and y is given by 
 
Assumptions:  
 linear relationship between x and y 
 continuous random variables 
 both variables must be normally distributed 
 x and y must be independent of each other 
Mander’s Coefficient: 
Mander’s coefficient is given by 
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 Ri is intensity of the first fluorophore in individual pixels and Rav arithmetic mean, 
whereas Gi and Gav are the corresponding intensities for the second fluorophore in the 
same pixels. Mander’s and Pearson’s coefficient are mathematically similar. Their only 
difference lie in utilization of absolute intensities (Mander’s coefficient) or the departure 
from the mean (Pearson’s coefficient). 
            5.3. Results and Discussion: 
Nuclear Extraction Uptake: To quantify nuclear uptake of NLS, nucleus was 
separated by sucrose gradient centrifugation. Fig.21A indicates nuclear uptake of FITC 
conjugated NLS peptides in both D407 and Y-79. Fig.21B indicates the specificity ratio of 
each NLS sequence. In order to quantify specificity of NLS for cancer vs non-cancerous 
cell nuclei, “specificity ratio”, has been defined as a ratio of nuclear uptake of NLS in Y-
79 vs D407 cell-lines. Higher the ratio, better the specificity of the modified NLS peptides 
for cancer cell nuclei.  
It is evident that nuclear uptake is higher in cancer cells compared to normal retinal 
cells for all modified peptides except for NLS4. NLS4 peptide exhibited significantly low 
nuclear uptake in both types of cells lacking any specificity. However, NLS3 peptide 
demonstrated a remarkably high nuclear uptake in Y79 cells compared to D407 cells. This 
NLS3 peptide exhibited highest affinity for cancer cell nuclei among all the NLS modified 
peptides with specificity ratio of 4.2. It is worth noting that replacement of phenyl alanine 
and lysine with VAL in NLS3 did not enhance nuclear uptake in cancer cells (compared to 
native NLS), instead these modifications significantly lowered nuclear uptake in normal 
cells resulting in higher specificity for cancer cell nuclei. The diminished affinity of NLS3 
towards normal cell nuclei may be attributed to second modification of LYS to VAL. Also 
NLS3 peptide appear to be optimum sequence. Hence, it can be inferred that this approach 
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might has the potential to provide NLS sequences having high affinity for cancer cell nuclei 
for targeted delivery. It has been hypothesize that by optimizing NLS sequences, specific 
targeting to cancer cell nuclei can be achieved.  
 
 
 
 
 
 
 
 
Fig. 21A and 21B-Specificity ratios of FITC tagged modified NLS 
peptides to nuclei of Y-79 D407 cells   showing preferential uptake of Y-79 
in Y-79 cells                   
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Fig.22: confocal image of free FITC uptake A-DAPI, B-cell membrane stain, C-
FITC D-Merge scale bar- 100 nm 
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Fig.23: confocal image of NLS 1 uptake-DAPI, B-cell membrane stain C-FITC 
tagged NLS 1 D-Merge scale bar- 100 nm 
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Fig.23 shows colocalization of NLS1 peptide with different cancerous and non-
cancerous cells. NLS 1 is the native peptide sequence with no modification incorporated. 
Hence according to our hypothesis NLS1 should not have any significant specificity 
towards malignant cells.   Fig.24 depicts plots showing ideal threshold for calculation of 
different coefficients for colocalization.  In case of NLS 1 colocalization within nucleus 
takes place for both non-malignant and malignant cells. Application of Costes’ automatic 
threshold (Fig.24) in images of uptake of NLS 1 in D407 yields Pearson’s coefficient of 
0.801, Mander’s coefficient are M1=0.995 and M2=0.92. The corresponding parameters 
with thresholding in Y-79, a retinoblastoma cell line is M1=0.908 and M=0.937 and 
Pearson’s coefficient is 0.737. Pearson’s coefficient for MCF10A using Costes’ threshold 
is 0.671 and Mander’s coefficients are M1=0.99 and M2=0.787. The corresponding values 
for T-47D are Pearson’s coefficient with costes automatic threshold is r=0.798 and 
Mander’s coefficient of M1=0.999 & M2=0.998. Same experiments were repeated in two 
other sets of cancer cell lines and their corresponding non-malignant cell lines. These are 
U87 (glioblastoma), CRL-2066(small cell lung cancer) and their corresponding non-
malignant cell lines astrocytes and lung fibroblasts. In case of glioblastoma the Pearson’s 
coefficient with thresholding is r=0.868 and Mander’s coefficient of M1=0.968 and 
M2=0.922 and for CRL-2066 Pearson’s coefficient with costes’ threshold is r=0.92 and 
Mander’s coefficients are M1=0.948 and M2=0.719. Corresponding values in normal cell 
lines are -for astrocytes Pearson’s coefficient is r=0.7 and Mander’s coefficient of 
M1=0.994 and M2=0.917. For lung fibroblasts with costes’ automatic thresholding 
Pearson’s coefficient is 0.855 and Mander’s coefficient is M1=0.932 and M2=0.765. 
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Fig.24: Costes’ Threshold for NLS 1 uptake in different cell lines:A-D407 B-
MCF10A C-Lung fibroblast D-Astrocytes E- Y-79 F-T47D G-CRL-2066 H-U87 
A 
B 
C 
D 
E 
F 
G 
H 
87 
 
 
Fig.25 shows cytofluorogram of NLS1 peptide with different cancerous and non-
cancerous cells. Application of Cytofluorogram parameters of a=0.769 and b=24.506  in 
images of uptake of NLS 1 in D407 yields correlation coefficient of 0.848.The 
corresponding cytofluorogram for Y-79, a retinoblastoma cell line with parameters of 
a=0.472 and b=1.547 is the correlation coefficient is 0.582 . For MCF 10A with parameters 
of a=0.226 b= 62.799 correlation coefficient: 0.662. The corresponding values for T-47D 
for parameters of a=0.915 and b=1.964 correlation coefficient: 0.816. For similar 
experiments repeated in two other sets of cancer cell lines (U87 (glioblastoma), CRL-
2066(small cell lung cancer) and their corresponding non-malignant cell lines (astrocytes 
and lung fibroblasts) similar results were obtained. In case of glioblastoma for parameters 
a=0.819 and b=4.281 correlation coefficient is 0.901 and for CRL-2066 for parameters 
a=0.739 and b=2.146 the correlation coefficient=0.874. Corresponding values in normal 
cell lines are -for astrocytes with parameters of a=0.257 and b=4.844 the Correlation 
coefficient is 0.795. For lung fibroblasts with parameters a=1.563 and b=6.2 correlation 
coefficient is 0.891. 
 
 
 
 
 
 
 
 
88 
 
 
 
 
 
 
 
 
 
Fig.25: Cytofluorogram for NLS 1 uptake in different cell lines:A-D407 B-
MCF10A C-Lung fibroblast D-Astrocytes E- Y-79 F-T47D G-CRL-2066 H-
U87 
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Fig.26: confocal image of NLS 2 uptake A-DAPI,B-cell membrane stain C-
FITCtagged NLS 2 D-Merge scale bar-100 nm 
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Fig.26 shows colocalization of NLS 2 peptide with different cancerous and non-
cancerous cells.   (Fig.27) depicts plots showing ideal threshold for calculation of different 
coefficients for colocalization. Application of Costes’ automatic threshold (Fig.27) in 
images of uptake of NLS 2 in D407 yields Pearson’s coefficient of 0.828, Mander’s 
coefficient are M1=0.973 and M2=0.993. The corresponding parameters with thresholding 
in Y-79, a retinoblastoma cell line is M1=0.959and M=0.849 and Pearson’s coefficient is 
0.446.Pearson’s coefficient for MCF10A using Costes’ threshold is 0.52 and Mander’s 
coefficients are M1=0.9 and M2=0.9. The corresponding values for T-47D are Pearson’s 
coefficient with Costes’ automatic threshold is r=0.812 and Mander’s coefficient of 
M1=0.993 & M2=0.998. Same experiments were repeated in two other sets of cancer cell 
lines and their corresponding non-malignant cell lines. These are U87 (glioblastoma), 
CRL-2066(small cell lung cancer) and their corresponding non-malignant cell lines 
astrocytes and lung fibroblasts. In case of glioblastoma the Pearson’s coefficient with 
thresholding is r=0.87 and Mander’s coefficient of M1=0.987 and M2=0.768 and for CRL-
2066 Pearson’s coefficient with costes’ threshold is r=0.563 and Mander’s coefficients are 
M1=0.889 and M2=0.768. Corresponding values in normal cell lines are -for astrocytes 
Pearson’s coefficient is r=0.532 and Mander’s coefficient of M1=0.894 and M2=0.663. 
For lung fibroblasts with costes’ automatic thresholding Pearson’s coefficient is 0.845 and 
Mander’s coefficient is M1=0.907 and M2=0.845 
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Fig.27: Costes’ Threshold for NLS 2 uptake in different cell lines:A-D407 B-
MCF10A C-Lung fibroblast D-Astrocytes E- Y-79 F-T47D G-CRL-2066 H-
U87 
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Fig.28 shows cytofluorogram of NLS 2 peptide with different cancerous and non-
cancerous cells. Application of cytofluorogram parameters of a=2.044 and b= -0.141  in 
images of uptake of NLS 2 in D407 yields correlation coefficient of 0.92.The 
corresponding cytofluorogram for Y-79, a retinoblastoma cell line with parameters of 
a=1.103 and b=9.273 is the correlation coefficient is 0.701 . For MCF 10A with parameters 
of a= -0.27 b= 53.932 correlation coefficient= -2.32. The corresponding values for T-47D 
for parameters of a=0.987 and b= -6.726 correlation coefficient: 0.844. For similar 
experiments repeated in two other sets of cancer cell lines U87 (glioblastoma), CRL-2066 
(small cell lung cancer) and) and their corresponding non-malignant cell lines (astrocytes 
and lung fibroblasts) similar results were obtained. In case of glioblastoma for parameters 
a=0.326 and b=7.251correlation coefficient is 0.743 and for CRL-2066 for parameters 
a=1.254 and b=1.896 the correlation coefficient=0.219. Corresponding values in normal 
cell lines are -for astrocytes with parameters of a=0.053 and b=1.896 the Correlation 
coefficient is 0.595. For lung fibroblasts with parameters a= 0.193 and b=0.752 correlation 
coefficient is 0.839. 
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Fig.28: Cytofluorogram for NLS 2 uptake in different cell lines:A-D407 B-
MCF10A C-Lung fibroblast D-Astrocytes E- Y-79 F-T47D G-CRL-2066 H-
U87 
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Fig.29: confocal image of NLS 3 uptake A-DAPI,B-cell membrane stain 
C-FITCtagged NLS 3 D-Merge scale bar- 100 nm 
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Fig.29 shows colocalization of NLS 3 peptide with different cancerous and non-
cancerous cells.   Fig.30 depicts plots showing ideal threshold for calculation of different 
coefficients for colocalization. Application of Costes’ automatic threshold (Fig.30) in 
images of uptake of NLS 3 in D407 yields Pearson’s coefficient of 0.013, Mander’s 
coefficient are M1=0.991 and M2=0.981. The corresponding parameters with thresholding 
in Y-79, a retinoblastoma cell line is M1=0.968 and M2=0.77 and Pearson’s coefficient is 
0.6. Pearson’s coefficient for MCF10A using Costes’ threshold is 0.09 and Mander’s 
coefficients are M1=0.998 and M2=0.81. The corresponding values for T-47D are 
Pearson’s coefficient with costes automatic threshold is r=0.9 and Mander’s coefficient of 
M1=0.989 & M2=0.97. Same experiments were repeated in two other sets of cancer cell 
lines and their corresponding non-malignant cell lines. These are U87 (glioblastoma), 
CRL-2066(small cell lung cancer) and their corresponding non-malignant cell lines 
astrocytes and lung fibroblasts. In case of glioblastoma the Pearson’s coefficient with 
thresholding is r=0.83 and Mander’s coefficient of M1=0.983 and M2=0.73 and for CRL-
2066 Pearson’s coefficient with costes’ threshold is r=0.82 and Mander’s coefficients are 
M1=0.988 and M2=0.979. Corresponding values in normal cell lines are for astrocytes 
Pearson’s coefficient is r=0.02 and Mander’s coefficient of M1=0 and M2=0. For lung 
fibroblasts with Costes’ automatic thresholding Pearson’s coefficient is 0 and Mander’s 
coefficient is M1=0 and M2=0. 
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Fig.30: Costes’ Threshold for NLS 3 uptake in different cell lines:A-D407 B-MCF10A C-Lung 
fibroblast D-Astrocytes E- Y-79 F-T47D G-CRL-2066 H-U87 
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Fig.31 shows cytofluorogram of NLS 3 peptide with different cancerous and non-
cancerous cells. Application of Cytofluorogram parameters of a=0.08 and b=19.05 in 
images of uptake of NLS 3 in D407 yields correlation coefficient of 0.135.The 
corresponding cytofluorogram for Y-79, a retinoblastoma cell line with parameters of 
a=1.033 and b=6.794 is the correlation coefficient is 0.628 . For MCF 10A with parameters 
of a=0.011 b= 3.93 correlation coefficient: 0.168. The corresponding values for T-47D for 
parameters of a=1.095 and b=24.498 correlation coefficient: 0.638. For similar 
experiments repeated in two other sets of cancer cell lines (U87 (glioblastoma), CRL-
2066(small cell lung cancer) and) and their corresponding non-malignant cell lines 
(astrocytes and lung fibroblasts) similar results were obtained. In case of glioblastoma for 
parameters a=0.021 and b=3.867 correlation coefficient is 0.73 and for CRL-2066 for 
parameters a=0.425 and b=0.054 the correlation coefficient=0.895. Corresponding values 
in normal cell lines are -for astrocytes with parameters of a=0.018 and b=19.974 the 
Correlation coefficient is 0.004. For lung fibroblasts with parameters a= -0.12 and b=5.7 
correlation coefficient is -0.347. 
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Fig.31: Cytofluorogram  for NLS 3 uptake in different cell lines:A-D407 B-
MCF10A C-Lung fibroblast D-Astrocytes E- Y-79 F-T47D G-CRL-2066 H-U87 
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Fig.32: confocal image of NLS 1 uptake A-DAPI,B-cell membrane stain C-
FITC tagged NLS 4 D-Merge scale bar- 100 nm 
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Fig.32 shows confocal images of NLS 4 peptide uptake with different cancerous 
and non-cancerous cells. (Fig.33) depicts plots showing ideal threshold for calculation of 
different coefficients for colocalization.. Application of Costes’ automatic threshold 
(Fig.33) in images of uptake of NLS 4 in D407 yields Pearson’s coefficient of 0.186, 
Mander’s coefficient are M1=0.977 and M2=0.766. The corresponding parameters with 
thresholding in Y-79, a retinoblastoma cell line is M1=0.934 and M2=0.968 and Pearson’s 
coefficient is 0.345. Pearson’s coefficient for MCF10A using Costes’ threshold is 0.171 
and Mander’s coefficients are M1=0.99 and M2=0.787. The corresponding values for T-
47D are Pearson’s coefficient with costes automatic threshold is r=0.548 and Mander’s 
coefficient of M1=0.998 & M2=0.935. Same experiments were repeated in two other sets 
of cancer cell lines and their corresponding non-malignant cell lines. These are U87 
(glioblastoma), CRL-2066(small cell lung cancer) and their corresponding non-malignant 
cell lines astrocytes and lung fibroblasts. In case of glioblastoma the Pearson’s coefficient 
with thresholding is r=0.304 and Mander’s coefficient of M1=0.989 and M2=0.778 and for 
CRL-2066 Pearson’s coefficient with costes’ threshold is r=0.493 and Mander’s 
coefficients are M1=0.922 and M2=0.891. Corresponding values in normal cell lines are -
for astrocytes Pearson’s coefficient is r=0.785 and Mander’s coefficient of M1=0.995 and 
M2=0.958. For lung fibroblasts with costes’ automatic thresholding Pearson’s coefficient 
is 0.655 and Mander’s coefficient is M1=0.943 and M2=0.943. 
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Fig.33: Costes’ Threshold for NLS 4 uptake in different cell lines:A-D407 B-
MCF10A C-Lung fibroblast D-Astrocytes E- Y-79 F-T47D G-CRL-2066 H-
U87 
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Fig.34 shows cytofluorogram of NLS 4 peptide with different cancerous and non-
cancerous cells. Application of cytofluorogram parameters of a=0.261 and b=11.634  in 
images of uptake of NLS 4 in D407 yields correlation coefficient of 0.517.The 
corresponding cytofluorogram for Y-79, a retinoblastoma cell line with parameters of 
a=1.111 and b=1.666 is the correlation coefficient is 0.696. For MCF 10A with parameters 
of a=0.661 b= 25.3 correlation coefficient: 0.739. The corresponding values for T-47D for 
parameters of a=0.53 and b=34.909 correlation coefficient: 0.733. For similar experiments 
repeated in two other sets of cancer cell lines (U87 (glioblastoma), CRL-2066(small cell 
lung cancer) and) and their corresponding non-malignant cell lines (astrocytes and lung 
fibroblasts) similar results were obtained. In case of glioblastoma for parameters a=1.972 
and b=8.261 correlation coefficient is 0.58 and for CRL-2066 for parameters a=2.287 and 
b=12.226 the correlation coefficient=0.668. Corresponding values in normal cell lines are 
-for astrocytes with parameters of a=0.2570.4 and b=7.4 the Correlation coefficient is 
0.852. For lung fibroblasts with parameters a=.173 and b= -0.994 correlation coefficient is 
0.728 
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Fig.34: Cytofluorogram for NLS 4 uptake in different cell lines:A-D407 B-MCF10A C-Lung 
fibroblast D-Astrocytes E- Y-79 F-T47D G-CRL-2066 H-U87 
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Fig.35: confocal image of NLS 5 uptake A-DAPI, B-cell membrane 
stain C-FITC tagged NLS 5 D-Merge scale bar-100 nm 
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Fig.35 shows colocalization of NLS 5 peptide with different cancerous and non-
cancerous cells. (Fig.36) depicts plots showing ideal threshold for calculation of different 
coefficients for colocalization. Application of Costes’ automatic threshold  in images of 
uptake of NLS 5 in D407 yields Pearson’s coefficient of 0.233, Mander’s coefficient are 
M1=0.99 and M2=0.752. The corresponding parameters with thresholding in Y-79, a 
retinoblastoma cell line is M1=0.952 and M=0.719 and Pearson’s coefficient is 
0.83.Pearson’s coefficient for MCF10A using Costes’ threshold is 0.134 and Mander’s 
coefficients are M1=0.723 and M2=0.697. The corresponding values for T-47D are 
Pearson’s coefficient with costes automatic threshold is r=0.732 and Mander’s coefficient 
of M1=0.991 & M2=0.941. Same experiments were repeated in two other sets of cancer 
cell lines and their corresponding non-malignant cell lines. These are U87 (glioblastoma), 
CRL-2066(small cell lung cancer) and their corresponding non-malignant cell lines 
astrocytes and lung fibroblasts. In case of glioblastoma the Pearson’s coefficient with 
thresholding is r=0.683 and Mander’s coefficient of M1=0.984 and M2=0.939 and for 
CRL-2066 Pearson’s coefficient with costes’ threshold is r=0.607 and mander’s 
coefficients are M1=0.993 and M2=0.798. Corresponding values in normal cell lines are -
for astrocytes Pearson’s coefficient is r=0.145 and Mander’s coefficient of M1=0.993 and 
M2=0.798. For lung fibroblasts with costes’ automatic thresholding Pearson’s coefficient 
is 0.085 and Mander’s coefficient is M1=0.28 and M2=0.524. 
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Fig.36: Costes’ Threshold for NLS 5 uptake in different cell lines:A-D407 B-
MCF10A C-Lung fibroblast D-Astrocytes E- Y-79 F-T47D G-CRL-2066 H-
U87 
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Fig.37 shows cytofluorogram of NLS 5 peptide with different cancerous and non-
cancerous cells. Application of cytofluorogram parameters of a=0.98 and b=10.068 in 
images of uptake of NLS 5 in D407 yields correlation coefficient of 0.105.The 
corresponding cytofluorogram for Y-79, a retinoblastoma cell line with parameters of 
a=0.701 and b= 8.758 is the correlation coefficient is 0.8 . For MCF 10A with parameters 
of a=0.014 b=7.993 correlation coefficient: 0.029. The corresponding values for T-47D for 
parameters of a=0.652 and b=17.701 correlation coefficient: 0.549. For similar 
experiments repeated in two other sets of cancer cell lines (U87 (glioblastoma), CRL-
2066(small cell lung cancer) and) and their corresponding non-malignant cell lines 
(astrocytes and lung fibroblasts) similar results were obtained. In case of glioblastoma for 
parameters a=0.508 and b=2.05 correlation coefficient is 0.839 and for CRL-2066 for 
parameters a=0.543 and b=2.138 the correlation coefficient=0.737. Corresponding values 
in normal cell lines are -for astrocytes with parameters of a=0.012 and b=3.277 the 
Correlation coefficient is 0.12. For lung fibroblasts with parameters a=0.045 and b=0.515 
correlation coefficient is 0.32 
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Fig.37: Cytofluorogram for NLS 5 uptake in different cell lines:A-D407 B-
MCF10A C-Lung fibroblast D-Astrocytes E- Y-79 F-T47D G-CRL-2066 H-
U87 
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It is clear from these results in the modified peptides acquire higher affinity for 
cancer cells. Incubation with FITC-tagged modified NLS peptides showed that nuclear 
uptake of peptides 3 and 5 are significantly higher in cancer cell nuclei relative to non-
malignant nuclei. Moreover, the results suggest that these two peptides’ penetrate in very 
low or negligible amounts across plasma membrane of normal cells. The Pearson’s 
coefficient and the cytofluorogram results clearly establish the preferential uptake of NLS 
3 and 5. Several cell-type specific interaction were observed. For example NLS 4 displayed 
colocalization in the nuclei of T4D but not in Y-79. And it was taken up by lung fibroblast 
nuclei more than by CRL-2066, the small cell lung cancer cell line. However no such cell 
type specific behavior was observed for NLS 3 and NLS 5. These two peptides exhibited 
uniform activity. These are being localized in the nuclei of all the cancerous cell line while 
they are not gaining entry into non-malignant cell nuclei in any appreciable quantity.  
unbound free FITC was used as control (Fig.22). It is a small molecule penetrates plasma 
and nuclear membranes of all cell lines without discrimination. Hence no co-localization 
study was performed with these samples .Table 4 lists the parameters for colocalization in 
all the cell lines for the five NLS peptides. 
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Table 4: Pearson’s coefficient and correlation coefficient of for different cell 
lines 
111 
 
            5.4. Conclusion: 
 
From nuclear extraction and confocal studies it is seen that NLS 3 and 5 has 
maximum affinity for cancer cell nuclei. Hence these two peptides will be selected for 
further studies in order to develop a targeted drug delivery system. Pearson’s coefficient 
and correlation coefficient provided colocalization data. This allowed us to screen and 
select peptides which were used for further analysis. Mander’s coefficient values were not 
proper and hence were not considered. 
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CHAPTER 6 
 
OPTIMIZATION OF PARAMETERS WITH RESPECT TO SIZE FOR 
FORMULATION DEVELOPMENT 
 
 
            6.1. Rationale: 
A majority of cancer chemotherapeutics elicit their pharmacological effect either 
in nucleus [135](like drugs employed in this study- doxorubicin and daunorubicin) or, in 
cytoplasm (like paclitaxel). Since this study is focused on the development of formulation 
for cancer chemotherapeutics, both cytoplasmic and nuclear targeted drugs have been 
selected to broaden the scope of this formulation development. However a majority of these 
drugs suffer from various disadvantages. One of the critical disadvantages in cancer 
chemotherapeutics is the development of drug resistance by tumor cells against these 
agents[136]. Consequently dose escalation is required to achieve therapeutic end point 
which leads to dose-related toxicity. Subsequently several drug delivery strategies have 
been devised by pharmaceutical scientists. In the current approach several nanoparticle 
formulations have been developed to optimize anticancer therapy. 
Following systemic administration NP may be delivered to tumors passively or 
actively. In case of passive delivery, NP can be designed to exhibit enhanced permeability 
and retention (EPR). EPR allows NP to surround tumor cells due to entry into extravascular 
space from systemic circulation [137]. However size of NP needs to be less than 100 nm 
[138]. In case of active delivery of NP, certain moieties like peptide and antibody are 
conjugated to nanoparticle surface which leads to preferential uptake of drug-loaded 
nanoparticles by tumor cells. The goal of this chapter is to optimize NP size in order to take 
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advantage of EPR effect. Also it has been mentioned earlier that a majority of anti-cancer 
drugs act in the nucleus. Therefore, it is important to deliver anti-cancer therapeutics across 
nuclear membrane. For any cargo to traverse crosses nuclear membrane it must travel via 
nucleopores -small pore like structures present on nuclear envelope. The internal diameter 
of nucleopore complex in 30-40 nm [139]. It is difficult to prepare NP in the size range of 
30-40 nm with required drug loading and entrapment efficiency. However with active 
targeting the nucleopore complex may expand and particles in the range of 60-70 nm can 
enter the nucleus[140].  This optimized formulation will eventually be exploited for active 
targeting so that NP are taken up specifically by cancer cells and cross nuclear membrane 
efficiently.  In order to achieve this goal, chemotherapeutics which exert their 
pharmacological effect in nucleus need to be formulated in within a size range of 60-70 nm 
[141]. For   drugs which act in cytoplasm, drug loaded NP are also required to be less than 
100 nm to take advantage of EPR effect[142]. Once this size objective is achieved targeting 
moieties, in this case NLS peptide screened in previous section will be conjugated to 
nanoparticles for specific uptake by tumor cells.  Hence this chapter optimizes parameters 
which will lead to preparation of NP of desired size.  
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Though nanoprecipitation (Fig.38) is a widely used technique, the selection of 
polymers remain very critical and is usually restricted to poly-lactic acid (PLA) and poly 
lactide-co-glycolide (PLGA)[143]. In this study PLGA conjugated with poly ethylene 
glycol (PEG) has been prepared. The reason for this triblock copolymer synthesis is that it 
allows conjugation of ligands on surface of nanoparticles for targeted delivery of anticancer 
therapeutics.  In this study chapter no ligand is attached. Once parameters are optimized 
and an efficient drug loaded nanoparticle is developed, the optimized formulation will be 
conjugated with a targeting moiety. PLGA is biocompatible as well as biodegradable [144]. 
It is approved by US FDA and is safely administered polymer widely employed for in vivo 
applications. Many investigators prepared PLGA-based nanocarriers to deliver a broad 
range of therapeutics including anticancer drugs and antioxidants[145]. Hence PLGA has 
been selected as polymer of choice. 
In this study PEG-bis-amine has been selected to conjugate PLGA. One amine 
group is utilized for conjugation with PLGA while the other remains free. This free amine 
Fig.38-A schematic representation of the nanoprecipitation methods applying 
dialysis in a membrane (A) and the dropping technique under stirring (B), 
respectively. 
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group will later be used to conjugate targeting moieties like peptides or antibodies. The 
reaction scheme is shown in Fig.39. 
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Fig.39- synthetic scheme of PLGA-PEG-NH2 
24 hours, inert condition, 
room temperature 
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            6.2. Materials and Methods: 
Materials: Poly (Lactic-co-glycolic acid) (50:50, molecular weight 8000) was 
purchased from Boehringer Ingelheim. Polyethylene Glycol bis-amine was acquired from 
Laysan Inc.  Organic solvents like dimethylformamide (DMF), acetone, tetrahydrofuran 
(THF), and acetonitrile were procured from Fisher Scientific. Anti-cancer drugs 
doxorubicin and daunorubicin were received from LC Laboratories, and paclitaxel was 
obtained from Biomol international. N-Hydroxysuccinamide, dicyclohexylcarbodiimide 
were received from Sigma Aldrich. 
            Methods: 
Synthesis of PLGA-PEG: Polymer preparation and its characterization were 
performed according to a published protocol with minor modifications [146]. Briefly 
PLGA was activated using DCC and N-hydroxysuccinimide (NHS) in dichloromethane 
with a molar ratio of DCC: NHS: PLGA= 1.2:1.2:1) under inert atmosphere for 24 hours. 
Activated PLGA was precipitated with ice-cold diethyl ether followed by filtration and 
vacuum drying for another 24 hours. Following this One gram of activated PLGA was 
dissolved in dichloromethane (5 mL). In another flask 2.1 g of PEG-bis-amine was 
dissolved in 2 mL of dichloromethane and added to PLGA drop-wise with PLGA:PEG-
bis-amine ratio of 1:5. The reaction mixture was stirred under an inert atmosphere. PLGA-
PEG-NH2 was purified by dialysis (MWCO:10 kDa) for 48 h to remove unreacted PEG-
bisamine . Following purification the polymer is freeze dried (VirTis Wizard 2.0 Freeze 
Dryer Control System).The reaction scheme is shown in Fig.40. 
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            Fourier Transform Infrared Spectroscopy (FTIR) analysis: 
FTIR spectroscopy was performed to confirm functional NH2 groups that were 
formed after conjugation of PLGA to NH2-PEG-NH2. An IR spectrum was recorded in a 
range of 650cm-1 to 4000cm-1 to 650cm-1 with a Perkin Elmer Spectrum One infrared 
spectroscopy. The resulting IR spectrum was analyzed with spectrum-v5.3.1 software. 
Fig.40: Synthetic scheme of PLGA-PEG diblock polymer 
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             1H-NMR analysis: 
Purity, molecular structure and molecular weight of PLGA-NH-PEG-NH2 polymer 
were analyzed utilizing a Varian 400-MHz NMR spectrometer. NMR spectroscopy was 
analyzed by dissolving the polymers in CDCl3.   
            Step 1: PLGA activation: 
Activation of PLGA was performed with dicyclohexylcarbodiimide (DCC) and N-
hydroxysuccinimide (NHS) in dichloromethane (DCM) (molar ratio of DCC: NHS: 
PLGA= 1.2:1.2:1). The reaction was carried out under inert condition for24h. Following 
activation PLGA was precipitated with ice-cold diethyl ether. After precipitation the 
polymer was filtered and dried in-vacuo for another 24h. 
Step 2- Synthesis of PLGA-PEG-NH2  
Activated PLGA (1 gm) from Step 1 was dissolved in 5 ml of DCM. In another 
flask 2.1 g of PEG-bis-amine was dissolved in 2 mL of DCM. PEG-bis-amine was then 
added carefully to PLGA solution drop-wise (PLGA: PEG-bis-amine:: 1:5). The resultant 
solution was slowly stirred under an inert nitrogen atmosphere for 24h. The resultant 
solution of PLGA-PEG-NH2 was purified by dialysis with a molecular weight cutoff of 10 
kDa against deionized water for 48h to remove unreacted PEG-bis-amine. Then the 
purified polymer was freeze dried (VirTis Wizard 2.0 Freeze Dryer Control System). 
Polymer Characterization: The polymer structure of PLGA-PEG was confirmed 
by 1H NMR spectroscopy (Varian-400 MHz NMR spectrometer) in deuterated dimethyl 
sulfoxide (DMSO-d6) and infrared spectroscopy.  
1H NMR: The structure of PLGA-PEG was confirmed by 1H NMR spectroscopy 
using Varian INOVA 400 MHz NMR spectrometer in DMSO-d6. Chemical shifts (δ) were 
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expressed in parts per million (ppm) relative to the NMR solvent signal (DMSO-d6) using 
tetramethylsilane as an internal standard. 
Infrared Spectroscopy: Ocean Optics UV-Vis-NIR was applied to detect 
functional groups in the synthesized polymer. Freeze-dried samples were stored for further 
analysis. 
Preparation of Blank Nanoparticle: Freeze dried polymer was processed for the 
preparation of NP by nanoprecipitation method following a published protocol with minor 
modifications[147]. Briefly PLGA-PEG-NH2 weighed and dissolved in organic phase. 
Then it was added drop wise into aqueous phase and stirred magnetically at room 
temperature to remove all traces of organic phase. Then the samples were freeze dried in 
presence of 15 mg of mannitol. In order to determine effect of different organic solvents 
on NP size several solvents i.e. acetone, acetonitrile, DMF and THF were selected for 
preparation.  Fig.41 represents the method of nanoprecipitation process. 
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Preparation of drug loaded nanoparticles: Anti-cancer agents are incorporated 
in the organic solvent and the organic phase was added to aqueous phase. Drug loaded NP 
are prepared following a similar protocol as described in the previous section for blank NP. 
Nanoparticle characterization:  
DLS size measurement: Nanoparticles (1 mg/mL) were dispersed in distilled 
deionized water to measure particle size. Average NP size was evaluated at room 
temperature by 90° scattering angel utilizing Zeta sizer (Zetasizer Nano ZS, Malvern 
Instruments Ltd, Worcestershire, UK). Polydispersity values were also measured and 
presented in Figure-7. All measurements were performed in triplicates. 
Loading and entrapment efficiency:  For measurement of  drug entrapment in 
nanoparticles, 2.0 mg of freeze-dried polymer was dissolved in 2 mL of organic solvent 
containing several concentrations of the anticancer agents   (Table-3) and mixed thoroughly 
for 24 h. The samples were then dried under inert atmosphere (nitrogen gas) and 
subsequently dissolved in 200 μL of acetonitrile: water (70:30). The mixtures was 
centrifuged at 12,000 g for 10 min at room temperature. The supernatant was aspirated for 
Fig.41- Nanoprecipitation method used for preparation of nanoparticles 
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analysis of drug content by HPLC (27). Entrapment efficiency and drug loading were 
calculated using Eqs. 1 and 2.  
Entrapment efficiency (%) = (Initial amount of drug- unentrapped amount of drug) 
X 100   Eq. 1                                                                                                                
                                                        (Initial drug amount)  
Drug loading (%) = (Initial amount of drug- unentrapped amount of drug) X100                    
Eq. 2  
                                                       (Weight of nanoparticles) 
 
            6.3. Results and Discussion: 
Polymer Preparation: The biodegradable copolymer PLGA-PEG-NH2 was prepared 
according to a previously published procedure with minor modifications [148]. 
 
            FTIR Analysis: 
FTIR spectroscopy was performed to confirm functional groups formed after 
conjugation of PLGA to NH2-PEG-NH2. The broad band (Fig.42) at 3545cm-1 represents 
the O-H stretch of the carboxylic acid at the end of PLGA, while the band at 3322.23 is N-
H stretching vibration band after formation of amide bond with carboxylic group on PLGA. 
The band at 2884.23 cm-1 correspond to –C-H stretching vibrations, C=O bond stretching 
vibration of carboxyl group appears at 1755.44cm-1, while the band at 1624.61cm-1 
belongs to C=O bond stretching vibration of –CONH group. The band at 1602 cm-1 relates 
to the bending mode of N-H vibration. The bands at 1100, 1241 and 1278.41cm-1 
correspond to C-O stretching vibration of the carboxylic group.  
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Fig.42-FTIR spectroscope of PLGA-PEG-NH2 
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1H-NMR analysis:  1H-NMR characteristic peaks were observed at 1.55 δ ppm 
which indicate protons from –CH3 group and 5.10-5.30 δ ppm assigned to protons of –
CH- group representing lactide units, respectively. A sharp peak at 3.64 δ ppm was 
accredited to methylene protons (-CH2CH2O-) of PEG, whereas, a cluster of peaks at 4.65-
4.90 δ ppm represent methylene protons (-CH2-) of glycolide units (Fig.43). The molar 
ratios of final product was calculated from integrations of PEG signal at 3.64 δ ppm and 
lactide/glycolide ratios of polymers were calculated from the peak intensities at 5.10-5.30 
δ ppm and 4.65-4.90 δ ppm . 
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Fig.43: NMR spectra of PLGA-PEG 
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Effect of solvent: In order to control size of nanoparticles, various organic phases 
were examined and effect on size of NP was observed. Four different organic phases 
(acetonitrile, acetone DMF and THF were tested.  A 15 mg of PLGA-PEG was dissolved 
in each of these solvents. According to previous reports miscibility of organic solvents in 
water influences size of nanoparticles139. Usually, miscibility is determined by comparison 
of solubility parameters (δ) of organic solvent and water. As solvents are increasingly 
miscible with each other, the difference between δ is progressively reduced. Increased 
water miscibility (lower Δδ) leads to reduction in average size of nanoparticles when all 
other parameters remain constant[149]. DMF is the most miscible solvent (lowest Δδ) 
among all the solvents used to dissolve the polymer. Hence nanoparticles prepared with 
DMF as organic phase generates lowest average size among all the solvents investigated. 
The average size of nanoparticles prepared with DMF is 106 nm.  
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0 20 40 60 80 100 120 140 160 180 200
PLGA-PEG NP 15 mg/ml acetone
PLGA-PEG NP 15 mg/ml in DMF
plga-peg NP  15mg/ml THF
plga-peg NP  15mg/ml acetonitrile
nanometer
Fig.44. Effect of different organic solvents on size of nanoparticles 
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Since the final target is nuclear drug delivery further reduction in size was 
necessary. Hence more optimization of formulation was necessary to obtain required size. 
The effect of various organic solvents is shown in Fig 44. These results demonstrate that a 
proper choice of organic phase solvent ratio is an important factor in the determination   of  
nanoparticle diameter. 
Effect of Polymer Concentration for Each of the Solvent: Polymer concentration 
also has significant influence on the size of nanoparticles.  Different polymer 
concentrations (5 mg/ml, 10 mg/ml, 15 mg/ml) dissolved in organic solvents has been 
studied. Effect on size due to variation in concentration of polymer dissolved in various 
organic phases is described below. For all organic solvents, the size of nanoparticles in 
general is reduced with lowering of polymer concentrations (Figs 45-48). This effect may 
be due to reduced viscosity of the dispersed phase (polymer solution)[150]. Reduced 
viscosity may enhance dispersability of the PLGA-PEG solution leading to smaller 
particles. A highly viscous solution results in greater resistance to mass-transfer[151]. 
Reduction in polymer concentration lowers viscosity of organic phase. It leads to enhanced 
distribution efficiency of polymer-solvent phase into the external phase. This process gives 
rise to formation of smaller NP. High viscous medium causes resistance to droplet-
disruption. It also lowers shear stresses in the organic phase.  Size distribution of NP is 
positively affected by net shear stress causing disruption of bigger droplets into smaller 
ones. 
Acetone: Several concentrations of polymers dissolved in acetone gave rise to three 
distinct mean size. As the polymer amount is reduced, NP size is reduced. When polymer 
concentration is lowered to 10 mg/ml from 15 mg/ml the size of NP slightly lowered from 
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162.4 nm to 156.2 nm.  When polymer concentration was further lowered to 5 mg/ml the 
size of nanoparticles drastically reduced to 109.3 nm. Fig.45 depicts the mean size of 
nanoparticles prepared with different concentrations of polymer dissolved in acetone. 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 50 100 150 200
 15 mg/ml
 10 mg/ml
  5mg/ml
nanometer
acetone
Fig.45. Effect of different polymer concentrations dissolved in 
acetone on NP size  
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DMF: When acetone is replaced with DMF as organic phase for preparation of NP 
with different polymer concentrations it had a pronounced effect on size of NP.  As 
discussed in the previous section superior miscibility of DMF in water creates a synergistic 
effect with polymer concentration influencing nanoparticle size. A variation in size of NP 
with change in polymer concentrations was higher than acetone. As polymer concentration 
is reduced from 15 mg/ml to 10 mg/ml, mean nanoparticle size diminished from 120.4 nm 
to 106.1nm. As polymer concentration was further reduced to 5mg/ml, the size became 
77.7 nm as shown in Fig.46.  This result indicates that DMF is a suitable organic phase in 
preparation of nanoparticles for nuclear delivery. 
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  15 mg/ml
 10 mg/ml
  5mg/ml
nanometer
DMF
Fig.46. Effects of different polymer concentrations dissolved 
in DMF on NP size  
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Acetonitrile: In case of acetonitrile as organic phase it was observed that change 
in polymer concentration did not exert any significant effect on size of NP. Fifteen mg/ml 
of PLGA-PEG in acetonitrile resulted in an average size of 151.27 nm. However 10 mg/ml 
of polymer resulted in an insignificant reduction of size to 144 nm while 5 mg/ml of 
polymer lowered mean size to 130.27 nm. But desired size range for nuclear drug delivery 
is around 60-70 nm. Even for therapeutics that do not act in nucleus, size of nanoparticles 
should be less than 100 nm to take advantage of EPR effect. Even with 5 mg/ml of polymer 
concentration the size of nanoparticle was much larger than 100 nm. Hence   acetonitrile 
was found to be not suitable for preparation of NP for cancer drug delivery. Fig.47 shows 
the effect of change in polymer concentration with acetonitrile as organic phase. 
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  15mg/ml
  10mg/ml
  5mg/ml
nanometer
Acetonitrile
Fig.47. Effects of different polymer concentrations dissolved 
in acetonitrile on NP size 
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THF: Tetrahydrofuran is a widely used solvent for NP preparation.   Effect of 
change in polymer concentration in THF on nanoparticle size has been investigated. Fifteen 
mg/ml of polymer resulted in NP with a mean size of 175.5 nm. For 10 mg/ml and 5 mg/ml 
polymer concentration the sizes of NP were 135.07 and 124.7 nm respectively. There was 
significant lowering in mean size of nanoparticle when polymer concentration was lowered 
from 15 mg/ml to 10 mg/ml. However the difference in size distribution between 10 mg/ml 
and 5 mg/ml is insignificant. Size range desired for our application ranged from 60-70 nm. 
However change in polymer concentration did not yield the desired size of nanoparticle 
with THF as organic phase. Hence we THF is not suitable for NP preparation intended for 
nuclear delivery. Fig .48 shows the effect of change in polymer concentration with THF as 
organic phase. 
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  15mg/ml
  10mg/ml
  5mg/ml
nanometer
THF
Fig.48.Effects of different polymer concentrations dissolved in THF on 
NP size 
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Effect of aqueous phase volume in different organic phases: In most of the 
studies mentioned, the ratio (volume) of aqueous phase to that of organic phase was kept 
constant. One part of organic phase with two parts of water was optimal.  However volume 
of aqueous phase plays a significant role in determination of nanoparticle size. Once the 
polymer concentration was optimized in organic phase, the volume of aqueous phase on 
the size of nanoparticle was investigated. Four ratios of aqueous to organic phase were 
selected. These are 1:1, 1:2, 1:5, and 1:10. Proportion of organic phase was kept constant 
while that of aqueous phase was varied. Previous studies revealed that acetone and DMF 
were the ideal organic phases and 5 mg/ml is the optimum polymer concentration. Hence 
these two solvents were selected for further optimization. 
Acetone: In general, size of nanoparticles diminishes with increase in amount of 
aqueous phase. However such relationship was not observed in our studies. In fact a slight 
increase in size was observed. The reason for this observation remains unexplained. It is 
possible that the organic phase plays an important role in size determination. The size of 
nanoparticles increased from 88.7 to 106.9 nm when the ratio of organic to aqueous phase 
volume was changed from 1:1 to 1:2. The size remained somewhat constant at 107.7 nm 
when the ratio was changed to 1:5. However the size further ascended to 115.2 nm when 
the ratio was changed to 1:10.  The explanation for this phenomena is that increase in size 
with aqueous phase is due to lower amount of organic phase available for controlling size 
of nanoparticles. Hence rise in water fraction causes rise in NP diameter. Change in 
aqueous phase volume on particle size with acetone as organic phase is shown in Fig.49. 
 
 
 
137 
 
 
 
 
 
 
 
 
DMF: In case of DMF, change in NP size with elevation of aqueous phase was different 
than of acetone. Initially rise in aqueous phase volume with respect to organic solvent results in 
diminution of NP size. As ratio of DMF to water was lowered from 1:1 to 1:2 diameter NP 
descended from 99.05 nm to 69.5.  However, NP size remained unaltered with increased aqueous 
phase relative to to organic phase from 1:2 to 1:5. The size remained constant at 69.5 nm.  Further 
increment in aqueous phase (1:10) led to size enhancement from 69.5 to 89.92 nm. It may be 
hypothesized that increase in aqueous phase beyond a critical volume leads to aggregation of 
particles. Effects of change in aqueous phase volume on particle size relative to DMF are shown 
in Fig.50. 
0 20 40 60 80 100 120 140
 acetone:water 1:1
 acetone:water  1:2
 acetone:water 1:5
 acetone:water 1:10
nanometer
Fig.49. Effects of aqueous and organic phases (acetone) 
ration on the size of NP  
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 DMF:water 1:1
 DMF:water 1:2
 DMF:water 1:5
 DMF:water 1:10
nanometer
Fig.50. Effects of aqueous and organic phases (DMF) ratio on the size of NP  
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Optimized parameters: Blank NP were prepared to optimize the parameters which 
will lead to effective delivery of cancer chemotherapeutics. For the preparation of drug 
loaded nanoparticles following parameters are optimized (Table 5). 
Variation of drug concentrations in different solvents: Effect on NP size: 
Preparation of drug-loaded nanoparticles of desired size is a difficult task. Three anti-
cancer drugs have been optimized doxorubicin, daunorubicin and paclitaxel with respect 
to organic phase, drug-loading and size of NP. Both doxorubicin and daunorubicin form 
Name 
of parameters 
Optimization 
Organic 
Phase 
DMF, 
Acetone 
Polymer 
concentration 
5 mg/ml 
organic 
and aqueous 
phase ratio 
1:2, 1:5 
Table 5: Optimized Parameters  
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complexes with DNA[152] while paclitaxel acts on microtubules in the cytoplasm. In order 
to cross the nuclear membrane chemotherapeutics need to be near 60 nm. In case of 
doxorubicin and daunorubicin loaded nanoparticles sixty nm size is essential for nuclear 
delivery. However paclitaxel does not need to cross the nuclear membrane as it acts in 
cytoplasm. To take advantage of the EPR effect, the size of paclitaxel loaded nanoparticles 
need to be less than 100 nm.  
Doxorubicin:  Doxorubicin is an anthracycline with cytotoxic properties. 
Doxorubicin conjugates to nucleic acids and acts by intercalation of its planar anthracycline 
nucleus with the DNA double helix located in the nuclei of cells[152].doxorubicin is 
indicated primarily in soft tissue and bone sarcomas, breast and ovarian carcinoma, 
transitional cell bladder carcinoma, thyroid carcinoma, gastric carcinoma, Hodgkin's 
disease, malignant lymphoma. However it is a very good substrate of efflux transporters 
located on the plasma and nuclear membranes [152]. Hence a high dose is required for 
therapeutic concentration at the site of action (nucleus). This high dose often leads to dose-
related toxicity and mortality. Hence it is necessary to evade efflux. Nanoparticle of PLGA-
PEG is an effective way to achieve that goal. However, only drug loaded NP of smaller 
size (<60nm) can cross nuclear membrane.  The optimum doxorubicin formulation is 
selected for nuclear delivery based on optimized parameters (Table.5). 
 
 
Acetone: Initially the organic phase selected to optimize doxorubicin loaded 
nanoaprticloes was acetone.three different concentrations of doxorubicins (1%, 5%,10%) 
were added  to prepare drug loaded NP.   1:2 and 1:5 ratio of acetone (organic) to acquous 
phase were applied. When the organic to aqueous phase was 1:2, for 10 % drug, the size 
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of NP was 378 nm. However when the ratio was changed to 1:5 the size increased to 1333 
nm. It is apparent that ascending water  content causes greater accumulation of hydrophilic 
drug in nanoparticles. The size was lower considerably when the concentration descended 
from 10 % to 5 %. For 5% doxorubicin concentration where organic to aqueous phase ratio 
was 1:2,  the mean NP size was 160 nm.As this ratio altered to 1:5, the size  reduced to 
137.4 nm. For 1% dox concentration the  NP size was further reduced. In case of 1:2 ratio 
,the size of drug loaded NP was 99.79 nm but when this ratio was  to 1:5 with 1% drug , 
NP size again rose to 105.07nm. If acetone was selected as organic phase 5% and 10% 
doxorubicin cannot be used to prepare nanoparticles. Only 1 % doxorubicin can be 
incorporated with 1:2 ratio of organic to aqueous phase. Fig.51 shows the size of different 
doxorubicin formulations prepared with acetone. 
 
 
 
 
 
0 200 400 600 800 1000 1200 1400 1600
acetone:water 1:2  1% doxorubicin
acetone:water 1:5 1% doxorubicin
acetone:water 1:2  5% doxorubicin
acetone:water 1:5 5% doxorubicin
acetone:water 1:5  10% doxorubicin
acetone:water 1:2  10% doxorubicin
nanometer
Fig.51. Size distribution of nanoparticles prepared with different 
concentrations of doxorubicin and altered ratio of acetone and water.  
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DMF: DMF applied as organic phase and the ratio of DMF to water 1:2 with 10% 
dox, generated nanoparticles well beyond detection because of very large size (more than 
40,000 nm).  This was probably due to aggregation of nanoparticles. Higher drug 
concentration possibly caused aggregation of nanoparticles. As the ratio of organic to 
aqueous phase was adjusted to 1:5, the size of doxorubicin loaded NP diminished to 188.95 
nm. However it is worth mentioning that acetone with a ratio 1:5 produced much bigger 
aggregated particles (1333 nm). In case of DMF the ratio of organic to aqueous phase was 
1:2 which caused large aggregated particles. It is evident from these observations that 
solvent plays an important role in NP aggregation. Further a decrease in drug concentration 
along with change in organic-aqueous phase ratio led to uniform lowering in size of 
nanoparticle. As drug concentration was lowered to 5 %, with organic to aqueous phase 
ratio of 1:2 and 1:5, the mean size of nanoparticles was reduced to 105 nm and 86.12 nm 
respectively. As drug concentration was further lowered to 1% with organic to aqueous 
phase ratio of 1:2 and 1:5, the nanoparticle size reduced to 68.93 nm and 61.8nm 
respectively. Hence it was concluded that DMF is the ideal solvent for doxorubicin loaded 
NP preparation. A 1% concentration and organic/aqueous phase ratio of 1:5 is the 
optimized conditions which might lead to effective nuclear drug delivery. Fig.52 shows the 
size of different doxorubicin formulations prepared with DMF. 
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0 50 100 150 200 250
DMF:water  1:5  1% doxorubicin
DMF:water  1:2  1% doxorubicin
DMF:water  1:5  5% doxorubicin
DMF:water  1:2  5% doxorubicin
DMF:water  1:5  10% doxorubicin
nanometer
Fig.52. Size distribution of nanoparticles prepared with 
different concentrations of doxorubicin and altered ratio of 
DMF and water.  
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Daunorubicin: Daunorubicin is another drug whose site of action is nuclei of 
malignant cells . It belongs to anthracycline family and is very similar to doxorubicin in 
structure and function. This drug also undergoes DNA intercalation very similar to 
doxorubicin. It is prescribed in specific malignancies like acute myelogenous leukemia and 
acute lymphoblastic leukemia. Daunorubicin has been found to be substrates of efflux 
pumps like P-glycoprotein and multi-drug resistance proteins.  Optimization of 
daunorubicin loaded nanoparticles with respect to size was performed. 
Acetone: As daunorubicin nanoparticles were prepared with acetone as organic 
phase there was a distinct variation in size. Organic to aqueous phase ratio was varied along 
with drug concentration. The different sizes obtained with changes in parameters are shown 
in Fig.53.  Acetone was not favorable organic phase for daunorubicin nanoparticles. The 
lowest size obtained with acetone was 134.7 nm. The drug concentration for that size was 
1% and organic to aqueous phase was 1:5.  Even 1% drug with organic to aqueous phase 
ratio of 1:2 resulted in nanoparticles of mean size of 212 nm. Hence optimized parameters 
with acetone as organic phase did not yield nanoparticles of desired size. Therefore acetone 
was not suitable for preparation of daunorubicin loaded nanoparticles.  
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0 100 200 300 400 500
 acetone 1:5   1%  daunorubicin
 acetone 1:2  1%  daunorubicin
 acetone 1:5  5%  daunorubicin
 acetone 1:2  5%  daunorubicin
 acetone 1:5 10%  daunorubicin
 acetone 1:2  10%  daunorubicin
nanometer
Fig.53. Size distribution of nanoparticles prepared with 
different concentrations of daunorubicin and altered ratio of 
acetone and water. 
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DMF: DMF produced better results as an organic solvent in respect to NP size. 
Nanoparticle was restricted below 100 nm for both 5% and 1% drug concentrations 
(Fig.54). For 5 % daunorubicin organic to aqueous phase at a ratio of 1:2 produced a mean 
size of 95.59 nm and for 1:5 ratio it was 96.2 nm. Hence effect of increased aqueous phase 
volume did not have affect the particle size. It caused a change when drug concentration 
was 10%. For a ratio of 1:2 with 10% drug the size of nanoparticles reached to 119 nm and 
for a ratio of 1:5 the size achieved was 145 nm.  Since these sizes were above the size range 
necessary for nuclear delivery further development was not considered. One interesting 
observation made for 10% daunorubicin was that the size range was however below 150 
nm. Hence it was assumed there was no aggregation unlike 10% doxorubicin nanoparticles. 
A slightly lower size was obtained when drug concentration adjusted to 1%. Daunorubicin 
loaded nanoparticles produced 75 nm and 77.3 nm with organic to aqueous phase ratio of 
1:2 and 1:5 respectively. If daunorubicin is to be delivered as nanoparticles DMF is 
preferred as organic phase with organic to aqueous phase ratio of 1:2 or 1:5 and drug 
concentration at 1%. A 5% drug loading may be considered as size of nanoparticles is 
below 100 nm. Such particles will probably not cross the nuclear membrane. However it 
has an advantage of generating EPR effect in tumor vasculature. It may also lower drug-
efflux out at plasma membrane. However it would probably be better to restrict size of 
nanoparticles in the range of 60-70 nm. Hence 1% daunorubicin is a preferred drug 
concentration for cancer drug delivery. 
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0 20 40 60 80 100 120 140 160 180
 DMF:water 1:2  1%  daunorubicin
 DMF:water 1:5  1%  daunorubicin
 DMF:water 1:2  5%  daunorubicin
 DMF:water 1:5  5%  daunorubicin
 DMF:water 1:2  10%  daunorubicin
 DMF:water 1:5  10%  daunorubicin
nanometer
Fig.54. Size distribution of nanoparticles prepared with different 
concentrations of daunorubicin and altered ratio of DMF and water.  
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Paclitaxel: Unlike doxorubicin and daunorubicin, paclitaxel does not act on 
nucleus but cytoplasm of malignant cells [153]. Paclitaxel disrupts microtubules which 
consequently prevents the cell division[154]. Hence paclitaxel arrests cancer cell growth. 
Thus paclitaxel loaded nanoparticles do not have to be in the range of 60-70 nm like 
doxorubicin and daunorubicin. However it is preferable to have the size lower than 100 nm 
to take advantage of EPR effect.  
 
Acetone: Similar to previous drugs the initial organic solvent selected for 
preparation of paclitaxel loaded nanoparticle was acetone. With acetone the largest particle 
size obtained was 91.5 nm and the lowest was 71.4 nm. The parameters which yielded 91.5 
nm nanoparticle were 10% paclitaxel with acetone and water ratio of 1:2. Fig.55 shows 
different size distribution of paclitaxel loaded nanoparticles with variation in parameters. 
Since paclitaxel does not act in the nucleus it does not require size of nanoparticle as low 
as 71.4 nm.  A 91.5 nm sized nanoparticle can be taken up by tumor vasculature. Since this 
size was obtained with 10% paclitaxel, this formulation with organic to aqueous phase ratio 
of 1:2 can deliver higher amounts of API for enhanced therapeutic effect. For organic to 
aqueous phase ratio of 1:5 with 10% paclitaxel NP size appeared to be 82.48 nm.  
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DMF: Following acetone, DMF was examined as organic phase to prepare 
paclitaxel loaded nanoparticles. Results were not much different with acetone as organic 
phase. Size of NP prepared with DMF was similar to acetone as organic phase. Paclitaxel 
loaded NP prepared with DMF and water ratio of 1:2 and 1:5, the size distribution was 89.6 
nm and 100.7 nm respectively. The corresponding NP size for acetone based nanoparticles 
were 91.5 nm and 82.48 nm respectively. Hence in case of paclitaxel nanoparticles no 
significant change in size was observed with respect to choice of organic phase. This 
pattern was observed for all three drug concentration investigated. The lowest size obtained 
with variation in parameter (1% drug, DMF to water ratio of 1:5) was 65 nm which was 
lower than formulation prepared with acetone which was 71.4 nm. In fact DMF as organic 
phase yielded smaller sized nanoparticles of all drug concentrations. Hence acetone was 
0 20 40 60 80 100
 acetone:water 1:5  1% taxol
 acetone:water 1:2  1% taxol
 acetone:water 1:5  5% taxol
 acetone:water 1:2  5% taxol
 acetone:water 1:5  10% taxol
 acetone:water 1:2  10% taxol
nanometer
Fig.55 Size distribution of nanoparticles prepared with 
different concentrations of paclitaxel and altered ratio of 
acetone and water.  
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selected to be the organic phase for preparation of paclitaxel loaded nanoparticles. Fig.56 
shows the size distribution of different paclitaxel formulations prepared with DMF. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
0 20 40 60 80 100 120
 DMF:water  1:2  1% paclitaxel
 DMF:water  1:5  1% paclitaxel
 DMF:water  1:2  5% paclitaxel
 DMF:water  1:5  5% paclitaxel
 DMF:water  1:2  10% paclitaxel
 DMF:water  1:5  10% paclitaxel
nanometer
Fig.56. Size distribution of nanoparticles prepared with different 
concentrations of paclitaxel and altered ratio of DMF and water.  
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Drug Loading and Entrapment Efficiency: Table 6 summarizes drug loading and 
encapsulation effieciency of all formulations prepared. Acetone yielded better entrapment 
efficiency compared to DMF for all three drugs. In case of DMF, organic to aqueous phase 
ratio of 1:5 gave marginally better encapsulation efficiency compared to ratio of 1:2. These 
results allow us to select the best formulation for anticancer drug delivery. Drug loading of 
all the formulations were within acceptable range of small molecule drugs. In some 
formulation with 10% drug concentration resulted in  high drug loading. However 
nanoparticles with 10% drug concentration did not yield desired size range and hence it 
was not considered. 
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Table 6. Percentage of Encapsulation Efficiency and Drug Loading of All Three Drugs for 
Optimized Formulations 
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In these studies  primary goal was  preparation of small size (60-70nm)  NP which 
is specifically needed for nuclear delivery through nucleopore.  the parameters  have been 
successfully optimized for preparation of nanoparticles with respect to size. The size of NP 
is a crucial factor which ensures its successful therapeutic application, particularly to the 
nuclear delivery of some anticancer agents acting on DNA . This approach can be 
replicated for other diseases like lysosomal storage diseases or inflammation,where 
successful targeted drug delivery requires particular size-range[154].  PLGA-PEG-NH2 
was selected not only because it allows for eventual conjugation of targeting moieties but 
also incorporation of PEG has been reported to increase longer systemic circulation of 
nanoparticles[155]. Cancer cells overexpress many proteins, including multidrug 
resistance proteins (efflux transporters)[156]. These transporters are responsible for 
effluxing  xenobiotics out of cells . These transporters identify chemotherapeutics as 
xenobiotics and efflux drugs out of cancer cells[157]. Efflux leads to subtherapeutic 
concentration. Eventually  high dosage is required leading to dose-related toxicity. A 
majority of anti-cncer drugs, including the three investigated in this report (doxorubicin, 
daunorubicin, paclitaxel) are excellent substrates of P-gp, MRP and BCRP. Incorporation 
of these therapeutics in PLGA-PEG NP prevent these molecules from being effluxed out 
of cancer cells by evading these transporters . Hence  NP serve two purposes: i) specifically 
taken up by tumor vasculature and cancer cell nuclei and  ii) evade efflux transporters 
overexpressed both on plasma and nuclear membranes of cancer cells. 
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 Parameters like organic solvents, organic to aqueous phase ratio, and drug 
concentrations for loading  have significant effects on the size of nanoparticles. Organic 
solvents in which drugs and polymers are solubilized  generate diverse  effects depending 
upon chemical nature of the material.  Variation in amount of polymer as well as drugs in 
each of these solvents, and the effect of different organic to aqueous phase ratio may change 
polymer crystalinity and ultimately size of nanoparticles. DMF and acetone  gave the best 
results with respect to  NP size . Both DMF and acetone show excellent miscibility with 
water. The organic to  aqueous phase ratio may have effect on polymer crystalinity which 
is controlling the size of nanoparicles. Ratios of  1:2 and 1:5 and 5 mg/ml  polymer were 
the selected concentration among three concentratins investigated (15 mg/ml,10mg/ml and 
5 mg/ml).   Three different drug concentrations (1%,5%,10%) have been tested. Each of 
these drug concentration yielded a batch of nanoparticle. Doxorubicin and daunorubicin 
are anthracyclines which act in  nuclei of deviding cells. Hence the NP need to be within 
the range of 60-70 nm to be able to cross nuclear membrane even with the help of ligands 
which travderses nucleopore complex in an energy-dependant process. The size of  
anthracyclins NP was controlled within this size range. This was successful with 
doxorubicin. However daunorubicin could not be formulated into nanoparticle within 60-
70 nm. The lowest size of daunorubicin nanoparticle obtained was 75 nm(Fig.19). Hence 
daunorubicin was not suitable as an anti-cancer chemotherapeutic to be formulated into 
small NP formulation.  
Therefore  doxorubicinwas selected as drug of choice. Two formulations of 
doxorubicin fit the criteria of size. The factors that yielded such nanoparticle are prepared 
fromDMF- water ratio of 1:5 with 5 mg/ml polymer with 1% doxorubicin whereas DMF 
water ratio of 1:2 with 5 mg/ml of polymer with 1% doxorubicin. The mean size of 
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nanoparticles prepared with these parameters were 63 nm and 70.49 nm respectively. The 
corresponding polydispersity are 0.139 and 0.123 which means the particles are fairly 
uniform. The size distribution profile of these two formulations are depicted in Figure 57 
a and b. 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.57. a) DMF water  ratio of 1:2, 5 mg/ml polymer  1% doxorubicin b) DMF 
water  ratio of 1:2   with 5 mg/ml of polymer and1% doxorubicin 
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Based on these  results   two batches of nanoparticles was selected as the 
formulation of choice. These particles will be further investigated for cytotoxic effects in 
cancer cells and preferential uptake by tumor and nuclei of cancer cells. These NP will also 
be conjugated with targeting moieties like peptides in further studies. 
Another set of formulations consist of two formulation of paclitaxel. These are 
prepared from acetone- water ratio of 1:5 with 5 mg/ml of polymer, and 10% drug and 
acetone-water ratio of 1:2 with 5 mg/ml of polymer and 10% drug. The sizes of 
nanoparticles prepared with these parameters were 82.48 nm and 91.5 nm respectively. 
Since paclitaxel acts in cytoplasm and does not need to enter the nucleus, for activity these 
sizes are acceptable. In order to take advantage of EPR effect the size of therapeutics need 
to be below 100 nm. These two formulations will also be investigated for their efficacy 
similar to doxorubicin. 
 
6.4. Conclusion:  
Various parameters have been investigated which yield appropriate nano 
formulation, ideal for drug delivery for cancer. Following optimization of several 
parameters two formulations each of doxorubicin and paclitaxel have been selected. These 
formulations have the desired size and polydispersity to be successful anti-cancer drug 
delivery platforms. Further investigation regarding efficacy and targeted delivery is 
discussed in next chapter. 
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CHAPTER 7 
 
EFFICACY AND MECHANISM OF TARGETED DELIVERY SYSTEM 
 
 
            7.1. Rationale: 
Following screening of peptides and development of nanoparticle formulation 
efficacy of targeted delivery system needs to be investigated. Also the reason for specificity 
of selected peptides for nuclei of cancer and its lack of affinity for non-malignant cell need 
to be understood. It is hypothesized that the peptides interact with some of the proteins 
responsible for traffic of cargo across the nuclear membrane.  
            7.2. Materials and Methods: 
            Conjugation of Peptide to doxorubicin nanoparticle: 
Carboxylic acid group of peptides will be activated by incubating them with N-
hydroxysuccinimide (NHS) and 1-(3-dimethylaminopropyl)-3-ethylcarbodimide 
hydrochloride (EDC) at room temperature with gentle stirring for 2 hours in a ratio of 1:2:2. 
Activated peptides are added to amine terminated PLGA-PEG nanoparticles and incubated 
in room temperature for 6 hours. The resultant NLS-conjugated nanoparticles are separated 
by centrifugation and resuspended in double distilled water (Fig.58). 
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Fig.58: Preparation scheme of functionalized nanoparticles 
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            Immunoblot Analysis:  
D407 and Y-79   cells were washed with PBS (3.2 mM Na2HPO4, 0.5 mM 
KH2PO4, 1.3 mM KCl, 135 mM NaCl) and lysed in PBS with 1% Triton X-100 with 
protease inhibitor cocktail at pH 7.4, for 15-20 min on ice. Upon homogenization, cells 
were centrifuged at 12,000 rpm for 10 min and the protein lysate collected. The amount of 
protein in the lysate will be determined using BCA protein assay reagent. An equivalent 
amount of protein (25 μg) in all samples were separated with polyacrylamide gel 
electrophoresis (PAGE). The protein was then transferred onto a polyvinylidene difluoride 
(PVDF) membrane and blocked overnight at 4°C with 2% non-fat dry milk and 0.25% 
BSA prepared in 0.05 M tris buffered saline. The blot was then exposed to primary P-gp 
antibody (Abcam, MA) at 37°C for 4 hours. After subsequent washes, the blot was then 
exposed to secondary antibody-goat anti rabbit HRP conjugate (Santa Cruz Biotechnology, 
Inc., CA). Finally the blot was visualized for the protein band using chemiluminescent 
substrate (Pierce Biotechnology, IL) in chemiImager 8900 (Alpha Innotech, CA). 
3D Cell Culture Model: To develop in-vitro 3D cell culture model PepGel 
PGmatrix (from PepGel LLC, Manhattan, KS) is utilized as per manufacturer’s protocol. 
The PGwork solution contains 1% standard peptide. Most cells grow well in 0.2%-0.5% 
peptide concentration.  0.5% PGworks solution is used for this set of experiments. 100µL 
PGworks solution is mixed with 900 µL cell suspension following which 1000 µL 
PGmatrix solution (gel) is gently added. The solution is mixed carefully without creating 
any bubble. A 250 µL cell suspension in PGmatrix solution is introduced into each well of 
a 4-well chamber slide. This PGmatrix solution matches to the cell culture medium. It is 
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then incubated at 370C for 30 min to allow gelation. Then a 250 µL of culture medium is 
added on the surface of hydrogel to prevent PGmatrix from drying. The 3D culture is 
allowed to grow for 7-9 days at 370C with 5% CO2 incubator. Culture medium on top of 
hydrogel is replaced every alternate day. After 7-9 days of culture, 500 µL of serum free 
medium is added on top of hydrogel layer. It is then disrupted by gentle mixing with plastic 
transfer pipet.  The hydrogel cell culture mix is transferred to centrifuge tubes and 
centrifuged at 1000-2000 g for 5min.  The supernatant is discarded and the pellet may be 
washed once again using serum free medium. Finally, the 3D culture is resuspended in 
serum free medium for staining or peptide/nanoparticle uptake studies. Also a 100 µL 
PGworks solution is mixed with 900 µL cell suspension and placed in T25 Flask Nunclon 
Sphera with 10mL of DMEM-F12 medium to grow 3D culture. Our FITC-tagged peptides 
or peptide conjugated nanoparticles encapsulating doxorubicin is utilized for uptake 
studies. Our model anti-cancer drug doxorubicin is auto fluorescent. Hence confocal laser 
microscopy is utilized to generate series of pictures at 8 µm depth interval. A minimum of 
40 pictures taken by confocal laser microscopy is applied to construct 3D cell culture 
picture with the aid of Image-J software (Fig.59). 
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Fig.59: 3D model of T47D 
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            Docking Studies:  
ZDOCK server is used for performing docking of NLS with importin alpha 2. Z-
dock is based on Fast Fourier Transform based protein docking program. 
Docking study of complexes using the Z-dock server is performed in three steps: 
(1) Input structures and options.  
(2) Selection of blocking/contacting residues 
(3) Viewing results. Users are emailed a link to the results page once the job is 
complete.  
The results depicts the complex as well as the docking score. The docking score 
shows the binding affinity of NLS peptides with the importin alpha 2. Higher the score 
more is the affinity of NLS for the importin protein. 
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            7.3. Results and Discussion: 
Fig.60. demonstrates binding of synthesized NLS peptides   to importin alpha 2. 
The docking scores of these complexes are presented in the Table 7. NLS 3 and NLS 5 
were found to have similar docking scores, and the scores of these two peptides are much 
higher than other three NLS peptides.  Importin alpha 2 has been reported to be 
overexpressed cancer cells [158]. This has been corroborated by Western blot analysis with 
protein isolated from Y-79 and D407. It was observed that KPNA2 or importin alpha 2 has 
a darker band in case of Y-79 compared to that of D407(Fig.61).Hence it is possible that 
enhanced interaction of importin alpha 2 with NLS 3 and NLS 5 leads to increased uptake 
of these NLS peptides into cancer cell nuclei.   
A 3D model for tumor to allow us to examine capacity of our NLS peptides to cross 
multiple cell layers as cancer is usually a complex system. A multi-channel 3D 
reconstruction of uptake of NLS 3 and 5 by a 3D tumor developed from T-47D cells is 
shown in fig.62. It has been observed that two of the synthesized peptides are quite 
efficacious in transporting nanoparticles across plasma and nuclear membrane of cancer 
cells in a 3D model of tumor (Fig.62 and 63).it was observed that doxorubicin loaded 
nanoparticles surface modified with NLS 3 and 5 resulted in significant accumulation of 
doxorubicin in the nuclei of T-47D cells while unmodified nanoparticle could not deliver 
doxorubicin efficiently to the nuclei. Most of the drug was clustered around the nuclear 
membrane as shown in figure 63. Images were taken at a depth of 320 micron via Z-
stacking. The Pearson’s co-localization co-efficient has been calculated for DAPI nuclear 
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stain and doxorubicin. The results are tabulated in table 8. It clearly shows accumulation 
of doxorubicin in case of nanoparticles surface modified with NL 3 and 5. 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.60: NLS importin complex Green ribbon-NLS peptide 
blue and red ribbon-importin alpha complex A-NLS1 B-
NLS2 C-NLS 3 D-NLS 4 E-NLS 5 
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Table 7: Docking score for peptides 
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Fig.61: western blot analysis of KPNA2 in 
D407 and Y-79 
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Fig.62: uptake of nanoparticles in a 3D model of T47D 
168 
 
 
 
                                                                                                                                                                                       
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig.63. Merged images showing co-localization of Doxorubicin and 
DAPI nuclear stain in a 3D model of tumor. Doxorubicin loaded 
nanoparticles surface modified with NLS 3 and 5 show much greater co-
localization compared to unmodified drug loaded nanoparticle and 
nanoparticle surface modified with NLS 1(native NLS).  
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Table 8: Pearson’s coefficient of 60 nm doxorubicin nanoparticles 
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            7.4. Conclusion: 
 
PLGA nanoparticle optimized in chapter 6 was conjugated with NLS peptides 
screened in chapter 5. It was observed that the approach of using NLS peptide for nuclear 
delivery of anti-cancer drug is adequately successful. It was able to deliver anti-cancer drug 
doxorubicin in 3D model of breast cancer. A 3D model mimics an actual tumor in terms of 
complexity. Hence it can be inferred that this strategy may work in-vivo. A nanoparticle 
formulation of optimum size with targeting moiety conjugated to it has the potential to 
lower toxicity associated with dose escalation related to off-target effects. 
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CHAPTER 8 
 
SUMMARY AND RECOMMENDATIONS 
 
 
            8.1. Summary: 
 
The purpose of this study is to develop a targeted delivery strategy for anti-cancer 
therapeutics. The focus of research is mainly delivery of the drugs to the nuclei of cancer 
cells specifically. Doxorubicin has been selected as a model anti-cancer drug.   In order to 
achieve this objective two strategies have been used a) PD modification b) development of 
modified NLS peptide for specific targeting of drug-loaded nanoparticles.  
The first strategy was to develop a novel peptide PD of doxorubicin which can 
bypass efflux transporters which are over-expressed in breast cancer cells. This approach 
has the potential to increase uptake and lead to higher drug accumulation in nuclei of cancer 
cells. The PD Val-Val-doxorubicin was found to be very stable in breast cancer cell 
homogenate. It was able to evade efflux pumps. The PD translocate across cytoplasm and 
nuclei of cancer cells by interacting with peptide transporters. Uptake of PD was found to 
be 10 fold higher than parent drug doxorubicin. However this strategy was not pursued 
further due to high stability and inability of PD to biorevert to its parent drug. This was due 
to the strong amide bond betwwn the peptide moiety L-val-L-val and doxorubicin. Hence 
despite the higher uptake the PD was unlikely to be efficacious. 
The second strategy adopted was development of modified NLS peptides for 
targeted delivery. It was observed that two NLSs- NLS3 and NLS5 showed specific uptake 
in cancer cell nuclei. Hence these two peptides were further investigated for their ability to 
carry drug-loaded nanoparticles across nuclei of cancer cells specifically. This was 
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observed to be a successful approach. The rationale for specificity of these peptides for 
cancer cell nuclei is their enhanced interaction with importins over-expressed in cancer 
cells as observed from docking studies. 
             8.2. Recommendations: 
The next step in this project will be performing in-vivo studies for the targeted 
nanoparticles. Also only hydrophobic modification of the peptides has been investigated. 
Modifications based on electrostatic, Hydrogen bonding and other interaction should be 
investigated. Also replacement of L-amino acids with D-amino acids i.e. investigation of 
stereo isomeric effect should be investigated as well.  This might lead to an even more 
potent targeting moiety with application potentially in wide ranging malignancies. Also 
these peptides should be conjugated to other drug-delivery platforms like nanomicelle so 
that these peptides are able to deliver a broader range of therapeutics. Also in-vivo studies 
need to be performed to analyze efficacy of the targeted nanoparticles developed in this 
project to reduce tumor size and volume without causing toxicity. 
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